Andrew Lees

Q: What Schools Are Affiliated With Andrew Lees

Andrew Lees is affiliated with the following schools: University of Leeds, University College London, University of East London, State University of Campinas, Johns Hopkins University, Queen Mary University of London, Massachusetts General Hospital, Monash University, Harvard University

Andrew Lees 's AcademicInfluence.com Rankings

Andrew Lees

Biology

#1385

World Rank

#2327

Historical Rank

Neuroscience

#93

World Rank

#98

Historical Rank

biology Degrees

Andrew Lees

Philosophy

#1509

World Rank

#2728

Historical Rank

Logic

#224

World Rank

#479

Historical Rank

philosophy Degrees

Download Badge

Biology
Philosophy

Andrew Lees 's Degrees

Doctorate Medicine Johns Hopkins University

Why Is Andrew Lees Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Andrew John Lees FRCP FRCP FMedSci is Professor of Neurology at the National Hospital for Neurology and Neurosurgery, Queen Square, London and University College London. In 2011 he was named as the world's most highly cited Parkinson's disease researcher.

(See a Problem?)

Andrew Lees 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. (1992) (9348)
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results (2008) (4378)
Diagnosis and management of dementia with Lewy bodies (2005) (3346)
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. (1988) (3245)
Ageing and Parkinson's disease: substantia nigra regional selectivity. (1991) (3193)
Second consensus statement on the diagnosis of multiple system atrophy (2008) (2532)
Clinical diagnostic criteria for dementia associated with Parkinson's disease (2007) (2413)
Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease (2004) (2294)
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation (2008) (1630)
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease (1989) (1392)
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study (2008) (1293)
The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. (2002) (1125)
Rivastigmine for dementia associated with Parkinson's disease. (2004) (1113)
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia (1994) (1093)
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan (2007) (1068)
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. (1991) (976)
A clinicopathologic study of 100 cases of Parkinson's disease. (1993) (949)
Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. (2005) (934)
Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force (2007) (918)
Cognitive deficits in the early stages of Parkinson's disease. (1983) (860)
What features improve the accuracy of clinical diagnosis in Parkinson's disease (1992) (852)
Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease (2001) (789)
A common LRRK2 mutation in idiopathic Parkinson's disease (2005) (739)
Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease (2012) (618)
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. (2009) (608)
Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. (2005) (576)
Parkinson's disease (2009) (566)
Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges (2009) (547)
What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study (2001) (544)
Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. (1991) (537)
A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease (1997) (531)
Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group (2000) (513)
A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra (1989) (512)
Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome (2004) (485)
Identification of common variants influencing risk of the tauopathy Progressive Supranuclear Palsy (2011) (481)
Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? (2011) (480)
Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies (2000) (474)
INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN (1987) (470)
Compulsive drug use linked to sensitized ventral striatal dopamine transmission (2006) (470)
Parkinson's Disease Society Brain Bank, London: overview and research. (1993) (456)
What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? (2010) (452)
Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group (2007) (450)
Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine (1992) (443)
The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. (2004) (434)
Striatal dopaminergic function in restless legs syndrome (1999) (433)
The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. (2004) (432)
The nighttime problems of Parkinson's disease. (1988) (429)
Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study (1994) (425)
A clinico-pathological study of subtypes in Parkinson's disease. (2009) (399)
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial (2017) (393)
The role of pathogenic DJ‐1 mutations in Parkinson's disease (2003) (387)
Parkinson's disease (vol 373, pg 2055, 2009) (2009) (384)
Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology (2006) (374)
Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability (2006) (362)
Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species (1998) (356)
A comparison of clinical and pathological features of young‐ and old‐onset Parkinson's disease (1988) (356)
Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. (2007) (353)
α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy? (2013) (349)
Exenatide and the treatment of patients with Parkinson's disease. (2013) (342)
Does corticobasal degeneration exist? A clinicopathological re-evaluation. (2010) (341)
Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. (2010) (339)
Intense oxidative DNA damage promoted by l‐DOPA and its metabolites implications for neurodegenerative disease (1994) (333)
PINK1 protein in normal human brain and Parkinson's disease. (2006) (333)
Parkin disease: a phenotypic study of a large case series. (2003) (332)
Visual dysfunction in Parkinson’s disease (2016) (326)
Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. (2005) (324)
Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis (2004) (323)
Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. (2008) (323)
Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease (1994) (315)
Tissue pH as an indicator of mRNA preservation in human post-mortem brain. (1995) (312)
Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. (2004) (312)
On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. (1984) (304)
SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS (1988) (300)
Deprenyl is metabolized to methamphetamine and amphetamine in man. (1978) (299)
Subcutaneous apomorphine in the treatment of Parkinson's disease. (1990) (297)
Glutathione‐related enzymes in brain in Parkinson's disease (1994) (295)
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease (1995) (290)
Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. (2011) (287)
Striatonigral degeneration. A clinicopathological study. (1990) (284)
Attention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regions. (2002) (283)
Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study (2005) (280)
Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease (2017) (278)
A Two-Stage Meta-Analysis Identifies Several New Loci for Parkinson's Disease (2011) (278)
Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. (1994) (272)
Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? (2003) (271)
Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). (1987) (270)
Clinical usefulness of magnetic resonance imaging in multiple system atrophy (1998) (270)
The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. (1995) (269)
Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study (2004) (268)
Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges (2005) (267)
SNCA variants are associated with increased risk for multiple system atrophy (2009) (263)
Decreased Ferritin Levels in Brain in Parkinson's Disease (1990) (259)
A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy (2014) (256)
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease (2006) (256)
The Psychopathology of the Gilles de la Tourette Syndrome (1988) (254)
Anti–basal ganglia antibodies in acute and persistent Sydenham’s chorea (2002) (254)
Nonmotor symptoms as presenting complaints in Parkinson's disease: A clinicopathological study (2008) (251)
Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration (2005) (251)
UCHL1 is a Parkinson's disease susceptibility gene. (2004) (247)
Early‐onset L‐dopa‐responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations (2010) (246)
Cognitive performance in recreational users of MDMA or 'ecstasy': evidence for memory deficits (1998) (245)
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD (2008) (243)
Tremor in Parkinson’s disease and serotonergic dysfunction (2003) (243)
Parkinson's disease, insulin resistance and novel agents of neuroprotection. (2013) (239)
Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease (1998) (239)
What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? (2000) (236)
Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series (2007) (235)
The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts (2007) (234)
The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. (2001) (234)
Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia (2010) (234)
Argyrophilic Grain Disease Is a Sporadic 4‐Repeat Tauopathy (2002) (232)
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial (2014) (231)
The clinical features and natural history of the Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy) (1986) (228)
Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: A clinical and electrophysiological study (2010) (227)
Olfactory function in atypical parkinsonian syndromes (1995) (226)
Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs (2003) (226)
Anticholinergics for symptomatic management of Parkinson's disease. (2002) (225)
Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson’s disease (2009) (223)
Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness. An experimental study. (1987) (223)
DEPRENYL IN PARKINSON'S DISEASE (1977) (217)
Management of Parkinson's disease: An evidence‐based review (2002) (217)
Dissection of the genetics of Parkinson's disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21 (2010) (215)
Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients (2002) (215)
Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. (2014) (214)
Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease (2005) (210)
Pure akinesia with gait freezing: A third clinical phenotype of progressive supranuclear palsy (2007) (210)
The genetics of Parkinson's syndromes: a critical review. (2009) (210)
The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. (2005) (209)
Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. (2000) (202)
Lewy body cortical involvement may not always predict dementia in Parkinson’s disease (2003) (200)
Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. (2006) (199)
Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule‐binding repeat domains as demonstrated by new specific monoclonal antibodies (2003) (199)
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial (2016) (199)
Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years (1993) (198)
Blood-based NfL (2017) (196)
Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations (2012) (196)
DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA (2008) (196)
The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease (1997) (194)
A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes (2015) (192)
Cognitive Deficits in Parkinson’s Disease (1985) (190)
Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. (1989) (189)
LIPID PEROXIDATION AS CAUSE OF NIGRAL CELL DEATH IN PARKINSON'S DISEASE (1986) (189)
Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson’s disease (2005) (187)
Pathophysiological differences between musician's dystonia and writer's cramp. (2005) (186)
Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies (2014) (185)
Clinical correlates of levodopa-induced dopamine release in Parkinson disease (2006) (185)
Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study (2006) (183)
Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. (2013) (183)
Kufor Rakeb Disease: Autosomal recessive, levodopa‐responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia (2005) (180)
Milestones in Parkinson's disease—Clinical and pathologic features (2011) (177)
Motor inhibition in patients with Gilles de la Tourette syndrome: functional activation patterns as revealed by EEG coherence. (2004) (177)
Low‐dose L‐dopa therapy in Parkinson's disease (1986) (177)
A heterozygous effect for PINK1 mutations in Parkinson's disease? (2006) (175)
Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. (2007) (174)
Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease (2019) (173)
Treatment of Parkinson's disease: levodopa as the first choice (2002) (172)
Natural history and syndromic associations of orthostatic tremor: A review of 41 patients (2004) (172)
Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease. (2010) (170)
Dopamine dysregulation syndrome in Parkinson's disease (2004) (169)
In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias (1997) (169)
ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation (2010) (168)
Intact Reward Learning but Elevated Delay Discounting in Parkinson's Disease Patients With Impulsive-Compulsive Spectrum Behaviors (2010) (168)
Adherence to antiparkinson medication in a multicenter European study (2009) (167)
Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. (1981) (167)
Tourette’s syndrome: a cross sectional study to examine the PANDAS hypothesis (2003) (166)
The impact of treatment with levodopa on Parkinson's disease. (1980) (166)
Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress (2006) (165)
Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players (2017) (165)
Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism. (1997) (165)
Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study (2018) (163)
Donepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety study (2012) (162)
Degeneration in Different Parkinsonian Syndromes Relates to Astrocyte Type and Astrocyte Protein Expression (2009) (161)
Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. (1995) (161)
Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial (2018) (161)
Parkinson’s disease in GTP cyclohydrolase 1 mutation carriers (2014) (160)
Self-injurious behaviour and the Gilles de la Tourette syndrome: a clinical study and review of the literature (1989) (160)
Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy (2012) (158)
The dopaminergic response in multiple system atrophy. (1992) (158)
Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease☆ (2014) (158)
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes (1990) (158)
Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy (2005) (157)
Dopamine Dysregulation Syndrome (2008) (157)
A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications. (1998) (156)
Olfaction and Parkinson's syndromes: its role in differential diagnosis (2004) (156)
Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. (2002) (156)
Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease: a dystonic phenomenon? (1988) (154)
A clinical study of Gilles de la Tourette syndrome in the United Kingdom. (1984) (153)
Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. (2002) (153)
Alpha-synuclein mRNA expression in oligodendrocytes in MSA (2014) (152)
Constipation preceding Parkinson's disease: a systematic review and meta-analysis (2015) (152)
Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis (2002) (151)
α-Synuclein fate is determined by USP9X-regulated monoubiquitination (2011) (151)
Encephalitis lethargica. A report of four recent cases. (1987) (147)
Dystonia in parkinson's disease: Clinical and pharmacological features (1988) (146)
Botulinum toxin A as treatment for drooling saliva in PD. (2000) (144)
Anal sphincter dysfunction in Parkinson's disease. (1989) (143)
Obsessional slowness. Functional studies with positron emission tomography. (1991) (142)
The nature of apraxia in corticobasal degeneration. (1994) (142)
The pre-morbid personality of patients with Parkinson's disease. (1985) (140)
The neurology of obsessional slowness. (1991) (138)
Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation (2005) (137)
Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease (2004) (137)
Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration (2014) (136)
Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease (2017) (136)
Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease. (2012) (136)
Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. (1988) (135)
Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. (1988) (135)
Progressive supranuclear palsy: where are we now? (2002) (134)
Unresolved issues relating to the Shaking Palsy on the celebration of James Parkinson's 250th birthday (2007) (134)
ROLE OF SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN VOIDING DYSFUNCTION (1988) (133)
The prediagnostic phase of Parkinson's disease (2016) (131)
Brain stem pathology in Parkinson's disease: An evaluation of the Braak staging model (2010) (129)
The effect of sleep on the dyskinetic movements of Parkinson's disease, Gilles de la Tourette syndrome, Huntington's disease, and torsion dystonia. (1991) (129)
Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial (2017) (128)
The structure of the tau haplotype in controls and in progressive supranuclear palsy. (2004) (128)
Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study (2017) (128)
Testing an aetiological model of visual hallucinations in Parkinson's disease. (2011) (127)
Olfactory function distinguishes vascular parkinsonism from Parkinson’s disease (2004) (127)
Tau gene and Parkinson’s disease: a case–control study and meta-analysis (2004) (124)
Neurological deterioration in young adults with phenylketonuria (1990) (124)
Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations. (2015) (124)
The auditory startle response in the Steele-Richardson-Olszewski syndrome and Parkinson's disease. (1992) (122)
A genome-wide association study in multiple system atrophy (2016) (122)
Do published criteria improve clinical diagnostic accuracy in multiple system atrophy? (2002) (122)
Dopamine agonists in Parkinson's disease: a look at apomorphine (1993) (117)
Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease (2004) (117)
The genetic and pathological classification of familial frontotemporal dementia. (2001) (117)
Parkin disease: a clinicopathologic entity? (2013) (116)
Diffusion‐weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple‐system atrophy from progressive supranuclear palsy (2007) (116)
The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases (1999) (115)
Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. (1989) (115)
Regional brain volumes distinguish PSP, MSA‐P, and PD: MRI‐based clinico‐radiological correlations (2006) (115)
Alternatives to Levodopa in the Initial Treatment of Early Parkinson’s Disease (2005) (114)
Cortical α-synuclein load is associated with amyloid-β plaque burden in a subset of Parkinson’s disease patients (2008) (114)
Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. (2004) (114)
Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. (1996) (114)
The on-off phenomenon. (1989) (113)
Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. (1998) (113)
Cognitive deficits in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). (1985) (111)
Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. A study of recent cases of postencephalitic parkinsonism and comparison with progressive supranuclear palsy and Guamanian parkinsonism-dementia complex. (1993) (111)
Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease (1995) (110)
Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. (2011) (108)
The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease (2013) (107)
Bone health in Parkinson's disease: a systematic review and meta-analysis (2014) (107)
A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy (2010) (106)
When did Ray Kennedy's Parkinson's disease begin? (1992) (106)
PRRT2 gene mutations (2012) (106)
What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy‐parkinsonism (PSP‐P)? (2010) (105)
Comparison of motor response to apomorphine and levodopa in Parkinson's disease. (1990) (105)
Bradykinesia akinesia inco-ordination test (BRAIN TEST): an objective computerised assessment of upper limb motor function (1999) (104)
Botulinum toxin treatment in spasmodic torticollis. (1990) (104)
Regional differences in the severity of Lewy body pathology across the olfactory cortex (2009) (104)
Using the presence of visual hallucinations to differentiate Parkinson’s disease from atypical parkinsonism (2007) (103)
Ten-year follow-up of three different initial treatments in de-novo PD (2001) (102)
The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. (2005) (101)
The midbrain to pons ratio (2013) (101)
Diaphragmatic flutter, the moving umbilicus syndrome, and “belly dancer's” dyskinesia (1990) (99)
Somatic mitochondrial DNA mutations in early parkinson and incidental lewy body disease (2012) (99)
An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies (2006) (99)
Role of DAT‐SPECT in the diagnostic work up of Parkinsonism (2007) (99)
The clinical features of Parkinson's disease in 100 histologically proven cases. (1993) (99)
Clinical genetics of familial progressive supranuclear palsy. (1999) (99)
Treatment of dystonic clenched fist with botulinum toxin (2001) (99)
Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study (2010) (98)
Multiple system atrophy–parkinsonism with slow progression and prolonged survival: A diagnostic catch (2012) (97)
[123I] FP‐CIT spect study in vascular parkinsonism and Parkinson's disease (2007) (97)
The substantia nigra and ventral tegmental area in Alzheimer's disease and Down's syndrome. (1989) (97)
UCHL‐1 is not a Parkinson's disease susceptibility gene (2006) (97)
PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome. (1994) (97)
Validation of the MDS‐UPDRS Part I for nonmotor symptoms in Parkinson's disease (2012) (95)
Sweating dysfunction in Parkinson's disease (2003) (95)
Challenge tests to predict the dopaminergic response in untreated Parkinson's disease (1991) (95)
Familial progressive supranuclear palsy. Description of a pedigree and review of the literature. (1995) (94)
Dopa‐responsive dystonia: [18F]dopa positron emission tomography (1991) (93)
PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results (2013) (93)
A validation exercise on the new consensus criteria for multiple system atrophy (2009) (92)
Diffuse Lewy body disease presenting with a supranuclear gaze palsy. (1991) (91)
Deficits in a tricarboxylic acid cycle enzyme in brains from patients with Parkinson’s disease (2003) (91)
Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia. (2001) (90)
Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. (1994) (90)
Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint (1999) (90)
Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry (1998) (90)
Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. (1996) (90)
Decision making, impulsivity, and addictions: Do Parkinson's disease patients jump to conclusions? (2012) (89)
The L266V tau mutation is associated with frontotemporal dementia and Pick-like 3R and 4R tauopathy (2003) (89)
An ambulatory dyskinesia monitor (2000) (89)
Neuronal inclusions of Parkinson's disease (1991) (89)
Spinal internuncial neurones in progressive encephalomyelitis with rigidity. (1979) (88)
Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease (2010) (88)
A new look at James Parkinson's Essay on the Shaking Palsy (2007) (88)
Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. (2001) (88)
Sensorimotor reorganization by proprioceptive training in musician's dystonia and writer's cramp (2008) (88)
Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT; comparison with Parkinson's disease and normal controls (1995) (87)
Writer's cramp: Treatment with botulinum toxin injections (1991) (87)
Progressive supranuclear palsy syndrome presenting as progressive nonfluent aphasia: A neuropsychological and neuroimaging analysis (2010) (87)
Alteration in α‐synuclein mRNA expression in Parkinson's disease (2004) (85)
Alzheimer's associated variant ubiquitin causes inhibition of the 26S proteasome and chaperone expression (2003) (85)
Akinetic freezing and trick movements in Parkinson's disease. (1980) (85)
The treatment of Gilles de la Tourette syndrome by limbic leucotomy. (1990) (85)
Discovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing (2017) (85)
The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. (1986) (84)
Brain iron deposition is linked with cognitive severity in Parkinson’s disease (2020) (84)
Abnormalities of the blink reflex in Gilles de la Tourette syndrome. (1989) (84)
A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. (1998) (83)
Management of Gilles de la Tourette syndrome using sulpiride. (1990) (83)
Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ‘cheese effect’ (1978) (83)
Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions (2014) (83)
The clinical phenomenon of akathisia. (1986) (83)
Effects of treatment on airway dynamics and respiratory muscle strength in Parkinson's disease. (1993) (83)
The identification of presymptomatic parkinsonism: Clinical and {18F}dopa positron emission tomography studies in an irish kindred (1992) (82)
Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation (2015) (81)
The Significance of α-Synuclein, Amyloid-β and Tau Pathologies in Parkinson's Disease Progression and Related Dementia (2013) (80)
SUBCUTANEOUS INFUSION OF APOMORPHINE AND LISURIDE IN THE TREATMENT OF PARKINSONIAN ON-OFF FLUCTUATIONS (1987) (80)
The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features (2012) (80)
Clinical features of parkinsonian patients with the α‐synuclein (G209A) mutation (2001) (79)
The l-dopa response in vascular parkinsonism (2004) (79)
Can the frontal assessment battery (FAB) differentiate bradykinetic rigid syndromes? Relation of the FAB to formal neuropsychological testing (2005) (78)
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. (2006) (78)
Randomized trial of tolcapone versus pergolide as add‐on to levodopa therapy in Parkinson's disease patients with motor fluctuations (2001) (77)
Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome (2019) (77)
Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs) (2009) (77)
A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. (2011) (77)
Problems in the Diagnosis of Progressive Supranuclear Palsy (Steele — Richardson — Olszewski Syndrome) (1978) (76)
CSF and serum immune parameters in Sydenham's chorea: evidence of an autoimmune syndrome? (2003) (76)
Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, A [11C]diprenorphine PET study. (1995) (75)
[123I]‐FP‐CIT‐SPECT demonstrates dopaminergic deficit in orthostatic tremor (2003) (75)
Punding and dyskinesias (2006) (75)
Parkinsonism and dystonia caused by the illicit use of ephedrone—A longitudinal study (2008) (75)
A randomized controlled pilot study to evaluate a technology platform for the assisted living of people with dementia and their carers. (2014) (75)
Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. (2002) (74)
Buspirone in the treatment of levodopa induced dyskinesias. (1991) (74)
Multiple system atrophy/progressive supranuclear palsy: α-Synuclein, synphilin, tau, and APOE (2000) (74)
Patterns of EMG–EMG coherence in limb dystonia (2004) (74)
Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases (2016) (74)
Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease (2012) (73)
Acute movement disorders with bilateral basal ganglia lesions in uremia (1998) (73)
Marijuana for parkinsonian tremor. (1990) (73)
Drooling in Parkinson's disease: a novel speech and language therapy intervention. (2001) (73)
The Parkinson chimera (2009) (72)
A pathological study of the association between Lewy body disease and Alzheimer's disease. (1989) (72)
CEREBRAL TUBERCULOMAS DEVELOPING DURING TREATMENT OF TUBERCULOUS MENINGITIS (1980) (72)
Prrt2 gene mutations: From paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine (2012) (72)
Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data (2016) (71)
Post-transcriptional regulation of mRNA associated with DJ-1 in sporadic Parkinson disease (2009) (71)
Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP‐CIT/SPECT study (2004) (70)
Can stress trigger Parkinson's disease? (2013) (70)
Four pioneers of L‐dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr (2015) (70)
Low dose quetiapine for drug induced dyskinesias in Parkinson’s disease: a double blind cross over study (2004) (70)
α‐tocopherol levels in brain are not altered in Parkinson's disease (1992) (70)
Parkinson's disease is not associated with the combined α‐synuclein/apolipoprotein E susceptibility genotype (2001) (69)
Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease. (2011) (69)
Screening for VPS35 mutations in Parkinson's disease (2012) (69)
Diffuse lewy body disease presenting with supranuclear gaze palsy, parkinsonism, and dementia: A case report (1992) (69)
Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine (2018) (68)
Dementia with Lewy bodies from the perspective of tauopathy (2003) (68)
Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies (2011) (68)
Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo‐controlled study (2010) (68)
Stroop test performance in impulsive and non impulsive patients with Parkinson's disease. (2011) (67)
Familial Parkinsonism and early onset Parkinson's disease in a Brazilian movement disorders clinic: Phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutations (2009) (67)
Movement disorders in 30 patients with tuberculous meningitis (2000) (67)
A study of the reproducibility of three different normalisation methods in intramuscular dual fine wire electromyography of the shoulder. (1998) (67)
Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. (1986) (67)
Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant (2014) (67)
Identification and Quantification of Oligodendrocyte Precursor Cells in Multiple System Atrophy, Progressive Supranuclear Palsy and Parkinson's Disease (2013) (66)
GLUCOCEREBROSIDASE MUTATIONS IN 108 NEUROPATHOLOGICALLY CONFIRMED CASES OF MULTIPLE SYSTEM ATROPHY (2009) (65)
Proton magnetic resonance spectroscopy in steele‐richardson‐olszewski syndrome (1997) (65)
EFFECT OF L-DOPA ON COURSE OF PARKINSON'S DISEASE (1984) (65)
Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: The role of electromyogram‐guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test (2006) (65)
The black stuff and Konstantin Nikolaevich Tretiakoff (2008) (64)
Post-streptococcal autoimmune dystonia with isolated bilateral striatal necrosis. (2002) (64)
Neurological soft signs in obsessive compulsive disorder: standardised assessment and comparison with schizophrenia. (1998) (64)
Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options (2016) (64)
Alteration in alpha-synuclein mRNA expression in Parkinson's disease. (2004) (63)
The use of smell identification tests in the diagnosis of Parkinson's disease in Brazil (2008) (63)
COMPARISONS OF THERAPEUTIC EFFECTS OF LEVODOPA, LEVODOPA AND SELEGILINE, AND BROMOCRIPTINE IN PATIENTS WITH EARLY, MILD PARKINSONS-DISEASE - 3-YEAR INTERIM-REPORT (1993) (63)
Neuropathological findings in benign tremulous Parkinsonism (2013) (63)
Stereotaxic injection of kainic acid into the striatum of rats induces synthesis of mRNA for heat shock protein 70 (1988) (62)
Dopaminergic Neuronal Imaging in Genetic Parkinson's Disease: Insights into Pathogenesis (2013) (62)
Development and assessment of sensitive immuno‐PCR assays for the quantification of cerebrospinal fluid three‐ and four‐repeat tau isoforms in tauopathies (2012) (62)
Impairment of EEG desynchronisation before and during movement and its relation to bradykinesia in Parkinson’s disease (1999) (61)
Idazoxan is ineffective for levodopa‐induced dyskinesias in Parkinson's disease (2000) (61)
Diagnostic considerations in juvenile parkinsonism (2004) (61)
Health‐related quality of life in patients with progressive supranuclear palsy (2003) (61)
The Slow Axonal Transport of the Microtubule-Associated Protein Tau and the Transport Rates of Different Isoforms and Mutants in Cultured Neurons (2002) (60)
Intranasal apomorphine: a new treatment in Parkinson's disease. (1990) (60)
Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward (2010) (59)
Novelty seeking behaviour in Parkinson's disease (2011) (58)
Serotonergic involvement in behavioural responses to amphetamine at high dosage (1979) (58)
THAP1 Mutations and Dystonia Phenotypes: Genotype Phenotype Correlations (2012) (58)
Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A (1998) (58)
A functional polymorphism regulating dopamine β‐hydroxylase influences against Parkinson's disease (2004) (57)
Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study (2006) (57)
Frontotemporal lobar degeneration with ubiquitin-only-immunoreactive neuronal changes: broadening the clinical picture to include progressive supranuclear palsy. (2004) (57)
Clinical correlation of brain MRI and MRS abnormalities in patients with Wilson disease (2004) (56)
The clinical features of pathologically confirmed vascular Parkinsonism (2012) (56)
Unusual focal dyskinesias: The ears, the shoulders, the back, and the abdomen (1994) (56)
New pathologic observations in juvenile onset parkinsonism with dystonia (1991) (56)
PREDICT‐PD: An online approach to prospectively identify risk indicators of Parkinson's disease (2017) (55)
Clinical and pathological features of an Alzheimer's disease patient with the MAPT ΔK280 mutation (2009) (55)
Physiological, pharmacological and neurohormonal assessment of autonomic function in progressive supranuclear palsy. (2000) (55)
Transportin1: a marker of FTLD-FUS (2011) (55)
Acute severe depression induced by intraoperative stimulation of the substantia nigra: a case report. (2008) (55)
Strong association of a novel Tau promoter haplotype in progressive supranuclear palsy (2001) (54)
Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. (1991) (54)
Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study. (2004) (53)
Association of MAPT haplotype-tagging SNPs with sporadic Parkinson's disease (2009) (53)
The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. (1989) (53)
High dose naltrexone for dyskinesias induced by levodopa (2001) (53)
MAPT S305I mutation: implications for argyrophilic grain disease (2008) (52)
Magnetic resonance spectroscopic study of parkinsonism related to boxing. (1995) (52)
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease (1997) (52)
Bromocriptine in parkinsonism. A long-term study. (1978) (51)
Evidence‐Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease (2008) (51)
New therapeutic indications for botulinum toxins (2004) (51)
Genome-wide analysis of the parkinsonism-dementia complex of Guam. (2004) (51)
Selegiline‐induced postural hypotension in Parkinson's disease: A longitudinal study on the effects of drug withdrawal (1999) (51)
Ten-year follow-up of three different initial treatments in de-novo PD: A randomized trial (2001) (50)
Descending control of muscles in patients with cervical dystonia (2002) (50)
Is sphincter electromyography a helpful investigation in the diagnosis of multiple system atrophy? A retrospective study with pathological diagnosis (2005) (50)
Transcriptional changes in multiple system atrophy and Parkinson's disease putamen (2006) (50)
A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease. (1987) (49)
Subcortical neurofibrillary degeneration presenting as steele‐richardson‐olszewski and other related syndromes: A review of 90 pathologically verified cases (1994) (49)
Applying a new version of the Brazilian-Portuguese UPSIT smell test in Brazil. (2010) (49)
The use of botulinum toxin in the treatment of adductor spasmodic dysphonia. (1993) (49)
Excessive hoarding in Parkinson's disease (2010) (49)
Premorbid personality and idiopathic Parkinson's disease. (1990) (48)
Normal pressure hydrocephalus or progressive supranuclear palsy? A clinicopathological case series (2012) (48)
Hyposmia in progressive supranuclear palsy (2010) (48)
Late Progression of Post-Encephalitic Parkinson's Syndrome (1988) (48)
Auctioneer's jaw: A case of occupational oromandibular hemidystonia (1995) (48)
TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT☆ (2013) (47)
Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease. (1992) (47)
Off‐period belching due to a reversible disturbance of oesophageal motility in Parkinso's disease and its treatment with apomorphine (1989) (47)
The effect of drug treatment on neurogenesis in Parkinson's disease (2011) (47)
Analysis of tau haplotypes in Pick’s disease (2002) (47)
The anatomy and pigmentation of the human substantia nigra in relation to selective neuronal vulnerability. (1990) (47)
Bradykinesia-Akinesia Incoordination Test: Validating an Online Keyboard Test of Upper Limb Function (2013) (47)
Complex stereotypies after right putaminal infarction: A case report (1991) (47)
The tau locus is not significantly associated with pathologically confirmed sporadic Parkinson's disease (2002) (46)
Hyposmia in pure autonomic failure (2009) (46)
Pathological gambling in Parkinson's disease—a review of the literature (2011) (46)
Giant cell arteritis with spinal cord infarction and basilar artery thrombosis. (1985) (46)
Parkinsonism and nigrostriatal dysfunction are associated with spinocerebellar ataxia type 6 (SCA6) (2005) (46)
Parkinson’s syndrome after closed head injury: a single case report (1999) (45)
Rectal apomorphine in Parkinson's disease (1991) (45)
No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer’s disease brain (2006) (45)
Pantothenate kinase-associated neurodegeneration is not a synucleinopathy (2012) (45)
Punding in Parkinson’s disease (2007) (45)
Remission in spasmodic torticollis. (1984) (45)
Minimal change multiple system atrophy: An aggressive variant? (2015) (45)
Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. (2001) (44)
Clinical features of childhood‐onset paroxysmal kinesigenic dyskinesia with PRRT2 gene mutations (2013) (44)
Disentangling the role of the tau gene locus in sporadic tauopathies. (2010) (44)
Salivary cortisol levels in Parkinson's disease and its correlation to risk behaviour (2011) (44)
Adapting the Sniffin' Sticks to diagnose Parkinson's disease in Sri Lanka (2009) (44)
A case of progressive subcortical gliosis presenting clinically as Steele-Richardson-Olszewski syndrome. (1988) (44)
The use of a color coded probability scale to interpret smell tests in suspected parkinsonism (2009) (44)
Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years. (1994) (44)
DJ-1 mutations in Parkinson's disease. (2004) (44)
Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa. (1979) (44)
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease (2006) (44)
Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A. (1995) (43)
The analysis of C9orf72 repeat expansions in a large series of clinically and pathologically diagnosed cases with atypical parkinsonism☆ (2015) (43)
Baclofen in Parkinson's disease. (1978) (43)
Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: An 18F‐dopa PET progression study (2009) (43)
Familial progressive supranuclear palsy: detection of subclinical cases using 18F-dopa and 18fluorodeoxyglucose positron emission tomography. (2001) (43)
The gene responsible for PARK6 Parkinson's disease, PINK1, does not influence common forms of parkinsonism (2004) (43)
"OFF PERIOD" DYSTONIA AND "ON PERIOD" CHOREOATHETOSIS IN LEVODOPA-TREATED PATIENTS WITH PARKINSON'S DISEASE (1977) (42)
Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease (1992) (42)
Phenylacetic acid in human body fluids: high correlation between plasma and cerebrospinal fluid concentration values. (1982) (42)
Botulinum toxin in the treatment of writer's cramp. (1996) (42)
Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition (2005) (42)
Differential DJ-1 gene expression in Parkinson's disease (2009) (42)
Normal dopamine transporter single photon‐emission CT scan in corticobasal degeneration (2008) (42)
PET studies on the integrity of the pre and postsynaptic dopaminergic system in Tourette syndrome. (1992) (42)
Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study (2020) (42)
BROMOCRIPTINE IN PARKINSON'S DISEASE (1978) (42)
Clinical aspects of impulsive compulsive behaviours in Parkinson's disease (2011) (42)
Adult‐onset tic disorder, motor stereotypies, and behavioural disturbance associated with antibasal ganglia antibodies (2004) (41)
Spinocerebellar ataxia type 17: Extension of phenotype with putaminal rim hyperintensity on magnetic resonance imaging (2005) (41)
4-repeat tauopathy sharing pathological and biochemical features of corticobasal degeneration and progressive supranuclear palsy (2003) (41)
The restless legs syndrome. (1986) (41)
Progressive supranuclear palsy (Steele-Richardson-Olszewski disease) (1999) (41)
Upregulation of dopamine D2 receptors in dopaminergic drug‐naive patients with parkin gene mutations (2006) (41)
Holmes tremor: Application of modern neuroimaging techniques (2006) (41)
Kinesigenic foot dystonia as a presenting feature of Parkinson's disease. (1984) (41)
The use of lisuride in the treatment of multiple system atrophy with autonomic failure (Shy-Drager syndrome). (1981) (41)
Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases☆ (2013) (41)
Progressive supranuclear palsy and its relation to pacific foci of the parkinsonism-dementia complex and Guadeloupean parkinsonism. (2002) (41)
Optimizing olfactory testing for the diagnosis of Parkinson’s disease: item analysis of the university of Pennsylvania smell identification test (2018) (40)
Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow‐up over 10 years (2005) (40)
Single versus multiple impulse control disorders in Parkinson’s disease: an 11C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release (2015) (40)
Neuropathology of primary adult-onset dystonia (2008) (40)
A clinical and pathological study of motor neurone disease on Guam. (2001) (40)
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease (2006) (40)
Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions (2019) (39)
The motor response to sequential apomorphine in parkinsonian fluctuations. (1991) (39)
The relationship between eye-winking tics, frequent eye-blinking and blepharospasm. (1989) (39)
Ethnic Variation in the Manifestation of Parkinson’s Disease: A Narrative Review (2019) (39)
Quantifying the impact of dyskinesias in PD (2007) (39)
Viral hepatitis and Parkinson disease (2017) (39)
Amyloid β‐peptide and the dementia of Parkinson's diease (1996) (39)
Dopamine agonists rather than deep brain stimulation cause reflection impulsivity in Parkinson's disease. (2013) (39)
Linked Clinical Trials – The Development of New Clinical Learning Studies in Parkinson’s Disease Using Screening of Multiple Prospective New Treatments (2013) (39)
Intranasal apomorphine in Parkinson's disease (1991) (39)
The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease. (1995) (39)
Uncertainty about mapping future actions into rewards may underlie performance on multiple measures of impulsivity in behavioral addiction: evidence from Parkinson's disease. (2013) (39)
The dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmoset (1986) (39)
Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy (1998) (38)
Impulsive‐compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy (2010) (38)
A geographical cluster of progressive supranuclear palsy in northern France (2015) (38)
Sporadic rapid‐onset dystonia–parkinsonism presenting as Parkinson's disease (2006) (38)
PARKINSON'S DISEASE AND DEMENTIA (1985) (38)
Neurofibrillary tangle parkinsonian disorders—tau pathology and tau genetics (1999) (38)
Sublingual apomorphine and Parkinson's disease. (1989) (38)
The neuroleptic malignant syndrome--a review. (1985) (38)
Clinical Neurophysiology in Parkinsonism (1986) (38)
Parkinson’s disease determinants, prediction and gene–environment interactions in the UK Biobank (2020) (37)
Immunohistochemical study of tau accumulation in early stages of Alzheimer-type neurofibrillary lesions (2004) (37)
Putaminal upregulation of FosB/ΔFosB-like immunoreactivity in Parkinson's disease patients with dyskinesia. (2011) (37)
Late onset startle induced tics (1999) (37)
Neuronal intranuclear inclusion disease: Report on a case originally diagnosed as dopa‐responsive dystonia with Lewy bodies (2005) (37)
Pathological gambling in Parkinson's disease (2007) (37)
Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease. (2011) (37)
HALLUCINATIONS AFTER WITHDRAWAL OF BACLOFEN (1977) (37)
Pisa syndrome in Parkinson's disease: a mobile or fixed deformity? (2013) (37)
Population based mortality and quality of death certification in progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) (2005) (37)
Olfactory heterogeneity in LRRK2 related Parkinsonism (2010) (37)
SPECT imaging of the dopamine transporter in juvenile-onset dystonia (2001) (37)
9.4 T MR microscopy of the substantia nigra with pathological validation in controls and disease (2016) (37)
High resolution MR anatomy of the subthalamic nucleus: Imaging at 9.4 T with histological validation (2012) (37)
Fiber-specific white matter reductions in Parkinson hallucinations and visual dysfunction (2020) (36)
Clinical heterogeneity of ATP13A2 linked disease (Kufor-Rakeb) justifies a PARK designation (2007) (36)
Morphometric changes in the reward system of Parkinson’s disease patients with impulse control disorders (2015) (36)
The corticotrophin‐releasing factor‐like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease (2007) (36)
Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series (2013) (36)
Paroxysmal dystonic head tremor (1991) (36)
Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease (2018) (36)
SUBCUTANEOUS APOMORPHINE AS A DIAGNOSTIC TEST FOR DOPAMINERGIC RESPONSIVENESS IN PARKINSONIAN SYNDROMES (1989) (35)
Drugs for Parkinson’s disease (2002) (35)
Anti-basal ganglia antibodies in patients with atypical dystonia and tics (2004) (35)
J. Clifford Richardson and 50 years of progressive supranuclear palsy (2008) (35)
Treatment of cervical dystonia hand spasms and laryngeal dystonia with botulinum toxin (2004) (35)
Difference in MSA phenotype distribution between populations: genetics or environment? (2012) (35)
Neuronal intranuclear inclusion disease and juvenile Parkinsonism (2000) (35)
The metabolic effects of limbic leucotomy in Gilles de la Tourette syndrome. (1993) (34)
DJ-1 (PARK7) is associated with 3R and 4R tau neuronal and glial inclusions in neurodegenerative disorders (2007) (34)
Assessment of common variability and expression quantitative trait loci for genome-wide associations for progressive supranuclear palsy (2014) (34)
Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence. (2016) (34)
Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. (2008) (34)
Screening performance of abbreviated versions of the UPSIT smell test (2018) (34)
Pattern of premature degenerative changes of the cervical spine in patients with spasmodic torticollis and the impact on the outcome of selective peripheral denervation (2000) (34)
Sporadic four-repeat tauopathy with frontotemporal degeneration, parkinsonism and motor neuron disease (2005) (33)
Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. (2017) (33)
Nitric oxide synthase mRNA expression in human subthalamic nucleus, striatum and globus pallidus: implications for basal ganglia function. (1994) (33)
HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness. (1994) (33)
Atypical unclassifiable parkinsonism on Guadeloupe: An environmental toxic hypothesis (2005) (33)
Adult‐onset tic disorders (2002) (33)
A case of progressive encephalomyelitis with rigidity and positive antiglutamic acid decarboxylase antibodies [corrected] (1991) (32)
Parkinsonism associated with acute intracranial hematomas: An [18F]dopa positron‐emission tomography study (1997) (32)
Apolipoprotein E e4 allele frequency in patients with multiple system atrophy (1997) (32)
Nocturnal and respiratory disturbances in Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). (1996) (32)
Measuring quality of life in PSP (2006) (32)
PINK 1 protein in normal human brain and Parkinson ’ s disease (2006) (32)
Use of smell test identification in Parkinson's disease in Mexico: A matched case‐control study (2011) (31)
Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype (2018) (31)
The pharmacology of foot dystonia in parkinsonism. (1987) (31)
Parkin maintains mitochondrial levels of the protective Parkinson’s disease-related enzyme 17-β hydroxysteroid dehydrogenase type 10 (2015) (31)
Dopaminergic function in patients with posttraumatic parkinsonism: An 18F-dopa PET study (1997) (31)
Torticollis due to disinhibition of the vestibulo‐collic reflex in a patient with Steele‐Richardson‐Olszewski syndrome (1997) (30)
Oligoclonal banding in the cerebrospinal fluid of patients with postencephalitic Parkinsonism. (1979) (30)
[123I]-FP-CIT-SPECT in the early diagnosis of PD presenting as exercise-induced dystonia (2002) (30)
Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders (2003) (30)
The α-synuclein gene in multiple system atrophy (2006) (30)
Cerebellar axial postural tremor (1997) (30)
Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease? (2016) (29)
MRI derived brain atrophy in PSP and MSA-P (2007) (29)
ODD AND UNUSUAL MOVEMENT DISORDERS (2002) (29)
Phenotypes, genotypes, and the management of paroxysmal movement disorders (2018) (29)
Clinical and pathological features of an Alzheimer's disease patient with the MAPT Delta K280 mutation. (2009) (29)
Neuronal intranuclear inclusion disease is genetically heterogeneous (2020) (29)
Unilateral pallidotomy for Parkinson’s disease: results after more than 1 year (1999) (29)
Tiapride in levodopa-induced involuntary movements. (1979) (29)
Increased reflection impulsivity in patients with ephedrone-induced Parkinsonism. (2013) (28)
Anticholinergic therapies in the treatment of Parkinson's disease (2002) (28)
Speech therapy in Parkinson's disease (2002) (28)
Shell shock at Queen Square: Lewis Yealland 100 years on (2013) (28)
Micrographia associated with a parietal lobe lesion in multiple sclerosis. (1994) (28)
Apomorphine in the diagnosis and treatment of parkinsonian tremor. (1990) (28)
A Retrospective Evaluation of the Frequency of Impulsive Compulsive Behaviors in Parkinson's Disease Patients Treated with Continuous Waking Day Apomorphine Pumps (2017) (28)
Sleep disturbance and impulsive-compulsive behaviours in Parkinson's disease (2010) (28)
Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy (2001) (28)
Olfactory impairment in familial ataxias (2012) (28)
Improvements in rate of development and magnitude of force with intense auditory stimuli in patients with Parkinson’s disease (2011) (28)
9.4T MR microscopy of the substantia nigra with pathological validation in controls and disease. (2017) (28)
Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study (1994) (28)
Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo*) compared to standard care in UK Parkinson's disease patients with wearing-off (2005) (28)
Is Transcranial Sonography Useful to Distinguish Scans Without Evidence of Dopaminergic Deficit Patients From Parkinson's Disease? (2012) (28)
Amyotrophic lateral sclerosis with dementia: an autopsy case showing many Bunina bodies, tau-positive neuronal and astrocytic plaque-like pathologies, and pallido-nigral degeneration (2006) (27)
Tau acts as an independent genetic risk factor in pathologically proven PD (2012) (27)
Diurnal differences in response to oral levodopa. (1990) (27)
Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease (1983) (27)
L-dopa treatment and Parkinson's disease. (1986) (27)
Diagnosing restless legs syndrome (RLS) in primary care (2004) (27)
Can olfactory bulb biopsy be justified for the diagnosis of Parkinson’s disease? Comments on “olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders” (2009) (26)
The auditory startle response in parkinsonism may reveal the extent but not type of pathology (2008) (26)
GPi Firing rate modification during beginning‐of‐dose motor deterioration following acute administration of apomorphine (1999) (26)
Sustained low-dose levodopa therapy in Parkinson's disease: a 3-year follow-up. (1983) (26)
Attention and cognition in bradykinetic‐rigid syndromes: An event‐related potential study (2001) (26)
Sequence analysis of tau in familial and sporadic progressive supranuclear palsy (2002) (26)
Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies (2020) (25)
TDP-43 in ubiquitinated inclusions in the inferior olives in frontotemporal lobar degeneration and in other neurodegenerative diseases: a degenerative process distinct from normal ageing (2009) (25)
Demographic and motor features associated with the occurrence of neuropsychiatric and sleep complications of Parkinson's disease (2013) (25)
Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations. (1991) (25)
The spectrum of involuntary vocalizations in humans: A video atlas (2019) (25)
Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications (1998) (25)
Heritability and genetic variance of dementia with Lewy bodies (2018) (25)
In vivo assessment of brain monoamine systems in parkin gene carriers: A PET study (2010) (25)
Incidental Lewy body disease in black Africans (1994) (25)
Genetic variation at the tau locus and clinical syndromes associated with progressive supranuclear palsy (2007) (24)
A genetic cluster of early onset Parkinson's disease in a Colombian population (2006) (24)
Organisational and neuromodulatory underpinnings of structural-functional connectivity decoupling in patients with Parkinson’s disease (2021) (24)
Smoking‐responsive juvenile‐onset Parkinsonism (2007) (24)
Progressive supranuclear palsy. (1999) (24)
Efficacy and safety of opicapone, a new COMT-inhibitor, for the treatment of motor fluctuations in Parkinson's Disease patients: BIPARK-II study (2013) (24)
Apomorphine in the treatment of Parkinson's disease: a review. (2018) (24)
A New family with frontotemporal dementia with intronic 10+3 splice site mutation in the tau gene: neuropathology and molecular effects (2005) (23)
TREATMENT OF PARKINSON'S DISEASE WITH NOVEL DOPAMINE D2 AGONIST SK&F 101468 (1989) (23)
NONCOMPRESSIVE MYELOPATHY ASSOCIATED WITH VIOLENT AXIAL TICS OF TOURETTE SYNDROME (2010) (23)
Selegiline hydrochloride and cognition (1991) (23)
L‐dopa–responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings (2004) (23)
Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. (2016) (23)
Ultrasound treatment of cutaneous side‐effects of infused apomorphine: A randomized controlled pilot study (2009) (23)
Severe dysphagia as a presentation of Parkinson's disease (2012) (23)
Safety Profile of Opicapone in the Management of Parkinson's Disease. (2019) (22)
Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and parkin‐linked Parkinson's disease (2006) (22)
Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy. (2004) (22)
Perceptual decision-making in patients with Parkinson’s disease (2014) (22)
Absence of disease related prion protein in neurodegenerative disorders presenting with Parkinson's syndrome. (1994) (22)
Hippocampal α-synuclein pathology correlates with memory impairment in multiple system atrophy. (2020) (22)
Use of apomorphine in Parkinson's disease. (1999) (22)
Concomitant progressive supranuclear palsy and chronic traumatic encephalopathy in a boxer (2014) (22)
Neuronal filaments in Alzheimer's, Pick's, and Parkinson's diseases. (1985) (22)
HALLUCINATIONS AFTER SUDDEN WITHDRAWAL OF BACLOFEN (1977) (22)
Telemedicine in Movement Disorders: Leçons du COVID‐19 (2020) (21)
Defining the ends of Parkin exon 4 deletions in two different families with Parkinson's disease (2005) (21)
Identical Twins with Leucine Rich Repeat Kinase Type 2 Mutations Discordant for Parkinson's Disease (2012) (21)
Trauma and Parkinson disease. (1997) (21)
Bilaterally coherent tremor resembling enhanced physiological tremor: Report of three cases (2002) (21)
Primary antiphospholipid syndrome presenting as a corticobasal degeneration syndrome (1999) (21)
DYT16: the original cases (2012) (21)
Development of a sensitive ELISA for quantification of three- and four-repeat tau isoforms in tauopathies (2009) (21)
MM2 subtype of sporadic Creutzfeldt-Jakob disease may underlie the clinical presentation of progressive supranuclear palsy (2013) (21)
Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy (2004) (21)
HEMIDYSTONIA RELIEVED BY NICOTINE (1984) (21)
Tau-positive grains are constant in centenarians’ hippocampus (2011) (21)
The motor prodromes of parkinson’s disease: from bedside observation to large-scale application (2019) (21)
PERGOLIDE AND LISURIDE FOR LEVODOPA-INDUCED OSCILLATIONS (1981) (21)
Foot dystonia in Parkinson's disease: clinical phenomenology and neuropharmacology. (1987) (21)
Pharmacokinetics of levodopa and motor fluctuations. (1987) (21)
The Motor Response to Repeated Apomorphine Administration in Parkinson's Disease (1991) (21)
Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. (2001) (20)
Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy (2018) (20)
Differential antagonism by neuroleptics of backward-walking and other behaviours caused by amphetamine at high dosage (1980) (20)
Progressive parkinsonism, balance difficulties, and supranuclear gaze palsy. (2014) (20)
Parkinson’s disease with Onuf’s nucleus involvement mimicking multiple system atrophy (2007) (20)
An essay on the shaking palsy (2017) (20)
Late onset ataxia: MSA‐C or SCA 17? A gene penetrance dilemma (2014) (20)
Banisteriopsis caapi, a Forgotten Potential Therapy for Parkinson's Disease? (2016) (20)
Mutational analysis of parkin and PINK1 in multiple system atrophy (2011) (20)
Parkinson's disease: a reduced ability to shift to a new grouping if not prompted or guided. (1990) (19)
Muscarinic Receptors in the Thalamus in Progressive Supranuclear Palsy and Other Neurodegenerative Disorders (2007) (19)
Subtle motor disturbances in PREDICT-PD participants (2016) (19)
Managing Parkinson's disease with continuous dopaminergic stimulation. (2008) (19)
Amantadine and other antiglutamate agents (2002) (19)
No pathogenic mutations in the synphilin-1 gene in Parkinson's disease (2001) (19)
Regional brain iron and gene expression provide insights into neurodegeneration in Parkinson’s disease (2021) (19)
Lack of association between progressive supranuclear palsy and arterial hypertension: A clinicopathological study (2003) (19)
The concept of bradyphrenia. (1994) (19)
Neuropathological features of Alzheimer's disease in non-demented parkinsonian patients. (1991) (19)
Torticollis after electrocution (1993) (19)
Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes (2019) (18)
BROMOCRIPTINE IN PARKINSONISM (1975) (18)
Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. (2021) (18)
The progression of idiopathic Parkinson's disease is not explained by age-related changes. Clinical and pathological comparisons with post-encephalitic parkinsonian syndrome (2004) (18)
Parkinson's disease: A broken nosology (2005) (18)
Banking on brains: Insights of brain donor relatives and friends from an experiential perspective (2012) (18)
A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients. (1996) (18)
Reversible coma in Wernicke's encephalopathy. (1985) (18)
Differences in network controllability and regional gene expression underlie hallucinations in Parkinson’s disease (2020) (18)
UCHL‐1 gene in multiple system atrophy: A haplotype tagging approach (2005) (18)
Altruistic punishment in patients with Parkinson's disease with and without impulsive behaviour (2011) (18)
Concomitant progressive supranuclear palsy and multiple system atrophy: More than a simple twist of fate? (2009) (17)
Dopamine reuptake transporter–single‐photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease (2018) (17)
Persistent rheumatic chorea (1985) (17)
A case of progressive subcortical gliosis associated with deposition of abnormal prion protein (PrP) (1995) (17)
Treatment of depression in idiopathic Parkinson's disease (2002) (17)
Down's syndrome and Parkinson's disease. (1997) (17)
GILLES-DE-LA-TOURETTES SYNDROME (1984) (17)
Concomitant fragile X-associated tremor ataxia syndrome and Parkinson's disease: a clinicopathological report of two cases (2014) (17)
Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease (2021) (17)
Frequency and significance of vocalizations in Sydenham's chorea. (2009) (17)
Effects of Age and Cognition on a Cross-Cultural Paediatric Adaptation of the Sniffin' Sticks Identification Test (2015) (17)
NR4A2 genetic variation in sporadic Parkinson's disease: A genewide approach (2006) (17)
Sign language tics in a prelingually deaf man (2000) (16)
Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias in Parkinson's disease. (1992) (16)
Attention to action in parkinson's disease (2001) (16)
A comprehensive screening of copy number variability in dementia with Lewy bodies (2019) (16)
New approaches in the use of selegiline for the treatment of Parkinson's disease (1989) (16)
Concept of bradyphrenia: a neuropsychiatric approach. (1987) (16)
Treatment of nonoccupational limb and trunk dystonia with botulinum toxin (1996) (16)
Evidence for pre and postsynaptic nigrostriatal dysfunction in the fragile X tremor–Ataxia syndrome (2009) (16)
Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson's disease. (1983) (16)
Melanized nigral neuronal numbers in Nigerian and British individuals (2006) (16)
International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease (1996) (16)
Schizophreniform Psychosis and Adrenomyeloneuropathy (1984) (16)
Reckless generosity in Parkinson's disease (2010) (16)
EMG–EMG coherence in writer's cramp (2002) (16)
Pathological substrate for regional distribution of increased atrophy rates in progressive supranuclear palsy (2004) (15)
Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study (2020) (15)
Hallucinations and parkinsonian motor fluctuations. (1992) (15)
The Neurobehavioural Abnormalities in Parkinson's Disease and their Relationship to Psychomotor Retardation and Obsessional Compulsive Disorders. (1989) (15)
Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl. (1979) (15)
Methysergide in progressive supranuclear palsy (1985) (15)
Alpha-tocopherol levels in brain are not altered in Parkinson's disease. (1992) (15)
Jumping to conclusions in untreated patients with Parkinson's disease (2016) (15)
Chorea in digoxin toxicity. (1984) (15)
BOTULINUM TOXIN : USEFUL IN ADULT ONSET FOCAL DYSTONIAS (1992) (15)
Progressive supranuclear palsy. (2007) (15)
Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers) (2015) (15)
Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson’s disease (2008) (15)
Hypoxic ischemia and proteasome dysfunction alter tau isoform ratio by inhibiting exon 10 splicing (2010) (14)
Letter: Bromocriptine and spasmodic torticollis. (1976) (14)
Psychedelic treatment of functional neurological disorder: a systematic review (2020) (14)
Olfactory function in Parkinson's disease in ON versus OFF states (2010) (14)
The effect of Banisteriopsis caapi (B. caapi) on the motor deficits in the MPTP‐treated common marmoset model of Parkinson's disease (2018) (14)
Problems with botulinum toxin treatment in mitochondrial cytopathy: case report and review of the literature (2005) (14)
Cardiovascular reflexes in Parkinson's disease: Effect of domperidone and apomorphine (1992) (14)
Lower nucleus accumbens α-synuclein load and D3 receptor levels in Parkinson's disease with impulsive compulsive behaviours. (2019) (14)
Levodopa therapy for Parkinson's disease: Challenges and future prospects (2008) (14)
Cerebral amyloid angiopathy and motor neurone disease presenting with a progressive supranuclear palsy‐like syndrome (2003) (14)
Parkinsonism due to Kernohan notch: Clinical, structural, and functional imaging correlates (2004) (14)
The Neuro-Behavioural Syndrome of Brainstem Disease (2008) (14)
The auditory startle response in progressive supranuclear palsy. (1994) (14)
Cigarette smoking, Parkinson's disease and ulcerative colitis. (1987) (14)
Drugs to treat dementia and psychosis (2002) (14)
Olfaction in pathologically proven patients with multiple system atrophy (2012) (14)
The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease. (1993) (13)
A Huntington's disease phenocopy characterized by pallido‐nigro‐luysian degeneration with brain iron accumulation and p62‐positive glial inclusions (2010) (13)
Georges Gilles de la Tourette. The man and his times. (1986) (13)
The relevance of the Lewy Body to the pathogenesis of idiopathic Parkinson's disease (2012) (13)
Mesulergine and pergolide in previously untreated Parkinson's disease. (1987) (13)
Levodopa Substitution: The Gold Standard (1994) (13)
Problematic Internet use in Parkinson's disease. (2014) (13)
Dopamine transporter imaging (2003) (13)
MAO‐B inhibitors for the treatment of Parkinson's disease (2002) (13)
The new Bradykinesia Akinesia Incoordination (BRAIN) test: Preliminary data from an online test of upper limb movement (2012) (13)
Impact Commentaries. A modern perspective on the top 100 cited JNNP papers of all time: The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease: accuracy of clinical diagnosis of idiopathic Parkinson's disease. (2012) (13)
Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies (2017) (13)
Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study (2004) (13)
A film of patients with movement disorders made in Queen Square, London in the Mid‐1920s by Samuel Alexander Kinnier Wilson (2011) (13)
LRP10 in α-synucleinopathies (2018) (12)
The clinical features of 67 patients with clinically definite Steele-Richardson-Olszewski syndrome. (1992) (12)
Gilles de la Tourette Syndrome 2nd edition (1989) (12)
A functional polymorphism regulating dopamine beta-hydroxylase influences against Parkinson's disease.(vol 55, 443, 2004) (2004) (12)
Prevalence of lewy bodies in alzheimer's disease (1989) (12)
Erich Harnack (1852–1915) and a Short History of Apomorphine (2013) (12)
BROMOCRIPTINE IN TREATMENT OF LEVODOPA-INDUCED END-OF-DOSE DYSTONIA (1980) (12)
The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties (2005) (12)
Selegiline and mortality in Parkinson's disease: Another view (1997) (12)
Jumpers (2001) (12)
Improving estimation of Parkinson’s disease risk—the enhanced PREDICT-PD algorithm (2020) (12)
Verbal adynamia in parkinsonian syndromes: behavioral correlates and neuroanatomical substrate (2018) (12)
Clinical and pharmacological aspects of (-)-deprenyl treatment in Parkinson's disease. (1983) (12)
Trial of subtherapeutic pergolide in de novo Parkinson's disease (2005) (12)
Pizza, mint, and licorice: Smell testing in Parkinson's disease in a UK population (2005) (12)
Identification of multiple system atrophy mimicking Parkinson’s disease or progressive supranuclear palsy (2021) (12)
Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)? (2015) (12)
Recent observations on the clinical pharmacology of (-)deprenyl (2005) (12)
Pathology of MPTP in the marmoset. (1987) (12)
The basal ganglia cholinergic neurochemistry of progressive supranuclear palsy and other neurodegenerative diseases (2006) (12)
An investigation of the mechanism involved in the cholinergic action of meptazinol (1987) (12)
Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study (2020) (12)
TDP‐43 pathology is present in most post‐encephalitic parkinsonism brains (2014) (11)
An intragenic duplication in guanosine triphosphate cyclohydrolase‐1 gene in a dopa‐responsive dystonia family (2011) (11)
The genetic and clinico‐pathological profile of early‐onset progressive supranuclear palsy (2019) (11)
Adapting the Sniffin' Sticks olfactory test to diagnose Parkinson's disease in Estonia. (2012) (11)
Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson’s disease treated with L-DOPA (2017) (11)
The BRadykinesia Akinesia INcoordination (BRAIN) tap test: capturing the sequence effect (2018) (11)
Does combined levodopa and bromocriptine therapy in Parkinson's disease prevent late motor complications? (1998) (11)
A pathological study of the association between Lewy body disease and Alzheimer's disease. (1990) (11)
Unified Parkinson's Disease Rating Scale (UPDRS) part I as a screening and diagnostic instrument for apathy in patients with Parkinson's disease. (2008) (11)
Subcutaneous and sublingual levodopa methyl ester in Parkinson's disease. (1991) (11)
How can neuroimaging help in the diagnosis of movement disorders? (2010) (11)
Psychogenic and neural visual-cue response in PD dopamine dysregulation syndrome. (2015) (11)
Apomorphine for Parkinson’s Disease (2002) (11)
Saccadic Direction Errors are Associated with Impulsive Compulsive Behaviours in Parkinson's Disease Patients. (2019) (11)
Polymyography Combined with Time-Locked Video Recording (Video EMG) for Presurgical Assessment of Patients with Cervical Dystonia (2001) (11)
A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. The U.K. Madopar CR Study Group. (1989) (10)
Parkinson's disease (2010) (10)
Safety and Efficacy of Tolcapone in the Long-term Use in Parkinson Disease: An Observational Study (2014) (10)
Effects of Dopamine on Sensitivity to Social Bias in Parkinson's Disease (2012) (10)
Posttraumatic tremor without parkinsonism in a patient with complete contralateral loss of the nigrostriatal pathway (2002) (10)
Cabergoline in the treatment of Parkinson’s disease (1988) (10)
SHORT REPORT A case of progressive encephalomyelitis with rigidity and positive antiglutamic acid dehydrogenase antibodies (10)
Tendency to late recurrence following rheumatic chorea (1989) (10)
Influence of target size on vertical gaze palsy in a pathologically proven case of progressive supranuclear palsy (2003) (10)
Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population. (2022) (10)
Interesting clinical features associated with mutations in the SLC20A2 gene (2012) (10)
USE OF APOMORPHINE TO TEST FOR DOPAMINE RESPONSIVENESS IN WILSON'S DISEASE (1989) (10)
A double-blind, controlled study of high-dose L-deprenyl in the treatment of Parkinson's disease. (1989) (10)
Bromocriptine in presenile dementia. (1978) (10)
Exaggerated startle reflexes in an elderly woman (1990) (10)
Development, characterisation and epitope mapping of novel monoclonal antibodies for DJ-1 (PARK7) protein (2005) (10)
Long-term effects of bromocriptine given to de novo patients with idiopathic Parkinson's disease. (1987) (10)
A common mutation in idiopathic Parkinson's disease (2005) (10)
Mortality in DATATOP (1999) (10)
Opsoclonus Myoclonus Syndrome associated with GQ1b Antibodies (2012) (10)
Queen Square: A History of the National Hospital and its Institute of Neurology (2018) (9)
Effect of adding selegiline to levodopa in early, mild Parkinson's disease - Reply (1996) (9)
Confirming Parkinson's disease with 123 I-FP-CIT SPECT (1999) (9)
Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations. (1987) (9)
Drugs to treat autonomic dysfunction in Parkinson's disease (2002) (9)
The controversial role of bromocriptine in Parkinson's disease. (1985) (9)
Longitudinal thalamic white and grey matter changes associated with visual hallucinations in Parkinson’s disease (2021) (9)
Letters to the editor (1990) (9)
Analysis of ATP13A2 in large neurodegeneration with brain iron accumulation (NBIA) and dystonia-parkinsonism cohorts (2012) (9)
Idiopathic Parkinson's disease combined with multiple system atrophy. A clinicopathological report (1991) (9)
Ropinirole (SK and F 101468) in the treatment of Parkinson's disease. (1991) (9)
In a rush to decide: deep brain stimulation and dopamine agonist therapy in Parkinson's disease. (2014) (9)
French Parkinson's Disease Genetics Study Group are Y. Agid, (2005) (9)
Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study (2005) (9)
ERGOT DERIVATIVES WITHOUT LEVODOPA IN PARKINSONISM (1979) (9)
Parkinson's syndrome associated with neurofibrillary degeneration and tau pathologic findings (2003) (9)
NEUROSYPHILIS TODAY (1979) (9)
SUBCUTANEOUS ADMINISTRATION OF APOMORPHINE IN THE MANAGEMENT OF FLUCTUATING MOTOR-PERFORMANCE COMPLICATING PARKINSONS-DISEASE (1988) (9)
Reporting clinical trials: full access to all of the data. (2002) (9)
Possible clinical overlap between postencephalitic parkinsonism and progressive supranuclear palsy. (1996) (8)
Histocompatibility antigens and post-encephalitic Parkinsonism. (1982) (8)
Nonparkinsonian tremors. (2000) (8)
The Outcome of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Retrospective Postmortem Study (2018) (8)
The design of a double-blind, placebo-controlled, multi-national phase-III trial in patients with Parkinson's disease and end-of-dose motor fluctuations: Opicapone superiority vs. placebo (2012) (8)
An Update on the Hardie Neuroacanthocytosis Series (2008) (8)
Reply to: “A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders” (2020) (8)
Yawning in Parkinson's disease. (1999) (8)
Dopamine agonists vs levodopa in impulse control disorders. (2011) (8)
Novel GCH1 mutation in a Brazilian family with dopa‐responsive dystonia (2008) (8)
The clinical diagnosis of multiple system atrophy presenting as pure parkinsonism. (1996) (8)
Using genome-Wwide complex trait analysis to quantify 'missing heritability' in Parkinson's disease (2012) (8)
MYORG-related disease is associated with central pontine calcifications and atypical parkinsonism (2020) (8)
Consequences of chronic 5-hydroxy-tryptophan in parkinsonian instability of gait and balance and in other neurological disorders. (1987) (8)
Long duration asymmetric postural tremor in the development of Parkinson’s disease (2004) (8)
Surgical treatment for Parkinson's disease: Deep brain surgery (2002) (8)
Editorial (2002) (8)
A Clinicopathologic Entity (2017) (8)
Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. (2019) (7)
Case of DYT1 dystonia triggered by bite from a moray (2006) (7)
The role of bromocriptine in the treatment of Parkinson's disease. (1980) (7)
DEMENTIA IN PARKINSON'S DISEASE (1987) (7)
Gowers’ Queen Square Case Notes on Chorea: A 21st Century Re-Appraisal (2012) (7)
Clinical-pathological study of subtypes in Parkinson's disease (2009) (7)
The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II (2021) (7)
Autosomal recessive late onset multisystem disorder with cerebellar cortical atrophy at necropsy: report of a family. (1984) (7)
Tourette's syndrome and the opioid system (1994) (7)
Facial mannerisms and tics. (1988) (7)
Non-motor manifestations of \Parkinson's disease (2004) (7)
Camptocormia: don’t forget muscle disease in the movement disorder clinic (2012) (7)
James Parkinson's Chimera: syndrome or disease? (2017) (7)
The Waiting Room: neurological observations made outside the movement disorder specialist’s consulting office (2019) (7)
The strange case of Dr. William Gowers and Mr. Sherlock Holmes. (2015) (7)
Current controversies in the use of selegiline hydrochloride. (1987) (7)
GROWTH-HORMONE RESPONSE TO BROMOCRIPTINE IN PARKINSONISM (1976) (7)
Falls and injuries in Progressive Supranuclear Palsy (PSP) (2002) (7)
TREATMENT OF WRITERS' DYSTONIA (1989) (7)
An 18F dopa PET study of disease progression and subclinical nigrostriatal dysfunction in a Parkin kindred (2001) (7)
Oral r‐(‐)‐11‐o‐valeryl‐n‐n‐propylnoraporphine reverses motor deficits in mptp‐treated marmosets (2016) (7)
Lack of pyramidal tract signs in Parkinson's disease (1992) (6)
Intact coupling of M1 receptors and preserved M2 and M4 receptors in the cortex in progressive supranuclear palsy: Contrast with other dementias (2008) (6)
Diagnosis of PD (1993) (6)
Anterior tibial compartment syndrome following prolonged tetany (1976) (6)
DA agonists ‐ Non‐Ergot derivaties: Ropinirole (2002) (6)
Addressing non-motor impairments in Parkinson's disease: The new version of the UPDRS (2005) (6)
PAW21 Rewarding visual cues increase dopamine neurotransmission in Parkinson's patients with impulse control disorders: a PET study (2010) (6)
Drugs for Parkinson's disease. (1978) (6)
Parkinson's Disease with Dementia (PDD) is the same clinicopathological entity as Dementia with Lewy Bodies (DLB) (2002) (6)
Neurology and detective writing (2013) (6)
Analysis of a distinct speech disorder seen in chronic manganese toxicity following Ephedrone abuse (2016) (6)
Efficacy and safety of opicapone in patients with Parkinson’s disease and motor fluctuations: 1-year follow-up (bipark I) (2015) (6)
A neuromyotonic process in a transposed latissimus dorsi muscle stemming from radiotherapy and peripheral surgery (1996) (6)
Lewy body disease (1989) (6)
Cutaneous side effects of infused apomorphine: The patient and carer experience (2008) (6)
Dystonia and cerebellar ataxia. (1990) (6)
Compulsive sexual behaviour in Parkinson’s disease is associated with higher doses of levodopa (2017) (6)
Smoking-induced transient motor deterioration in a levodopa-treated patient with Parkinson’s disease (2012) (6)
Dopamine neurotransmission, Parkinson’s disease and SPET (2001) (6)
Striatal expression of FosB-related transcription factors in human Parkinson's disease: Relation to L-dopa-induced dyskinesia (2002) (6)
Yorkshire's influence on the foundation of British Neurology (2012) (6)
DA agonists ‐ Ergot derivaties: Cabergoline (2002) (6)
Psychosocial counseling in Parkinson's disease (2002) (6)
Bradykinesia in Parkinson's Disease and Related Conditions (2010) (6)
William Gowers: the never completed third edition of the 'Bible of Neurology'. (2012) (6)
MSA‐C or SCA 17? A clinicopathological case update (2016) (6)
Web‐based assessment of Parkinson's prodromal markers identifies GBA variants (2015) (6)
Parkinsonism following electrical injury to the hand (1998) (6)
CONSTIPATION PRECEDING PARKINSON'S DISEASE–META-ANALYSIS (2015) (6)
Medical conferences: value for money? (2018) (6)
Surgical treatment for Parkinson's disease: Neural transplantation (2002) (6)
Inverse masticatory muscle activity due to syringobulbia (1993) (5)
Konstantin N. Tretiakoff in Brazil: a historical perspective and discussion of his contribution to brazilian neuroscience. (2009) (5)
Lesion of the dorsorostral midbrain sparing the nigrostriatal tract mimics axial rigidity seen in progressive supranuclear palsy (2005) (5)
Physical and occupational therapy in Parkinson's disease (2002) (5)
[Andrew Lees «Mentored by a Madman: The William Burroughs Experiment»]. (2017) (5)
Managing motor fluctuations, dyskinesias, and other adverse effects in Parkinson's disease (1994) (5)
Parkinson disease: How reliable are prodromal indicators of Parkinson disease? (2015) (5)
Encephalomyelitis with rigidity complicating human immunodeficiency virus infection (2002) (5)
Familial camptocormia: from dystonia to myopathy (2011) (5)
Case 2, 1991: Unusual tremor, myoclonus, and a limping gait (1991) (5)
TIAPRIDE AND SULPIRIDE IN PARKINSON'S DISEASE (1978) (5)
Pooled efficacy of opicapone as adjunctive therapy to levodopa in patients with Parkinson’s disease and motor fluctuations (2016) (5)
The midbrain to pons ratio A simple and specific MRI sign of progressive supranuclear palsy (5)
Clinical correlates of levodopa-induced increases in brain dopamine levels in Parkinson's disease: An C-11-raclopride PET study (2005) (5)
An Introduction to Progressive Supranuclear Palsy (1995) (5)
Changes in dynamic transitions between integrated and segregated states underlie visual hallucinations in Parkinson’s disease (2021) (5)
Pathological substrate of memory impairment in multiple system atrophy (2022) (5)
Reporting clinical trials: Full access to all the data (2002) (5)
The Parkinson’s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson’s Disease in Patients and their Carers (2021) (5)
Failure in heat-shock protein expression in response to UBB+1 protein in progressive supranuclear palsy in humans (2004) (5)
Late Emergence of Parkinsonian Phenotype and Abnormal Dopamine Transporter Scan in Chorea‐Acanthocytosis (2015) (5)
Motor Dysfunction as a Prodrome of Parkinson's Disease. (2020) (5)
The true face of James Parkinson (2018) (5)
Efficacy of opicapone versus entacapone in catechol-O-methyltransferase inhibitor-naïve Parkinson's disease patients recently diagnosed with motor fluctuations: a post-hoc conservative analysis (2020) (5)
Common variation at the LRRK2 locus is associated with survival in the primary tauopathy progressive supranuclear palsy (2020) (5)
Neuropathological Findings in Ephedrone Encephalopathy (2020) (5)
Reply to Jack E. Riggs' "Deprenyl, excess mortality, and epidemiological traps". Parkinson's Disease Research Group of the United Kingdom. (1998) (5)
Atypical parkinsonism in the French West Indies (1999) (5)
Visual dysfunction predicts cognitive impairment and white matter degeneration in Parkinson’s disease (2020) (5)
Tau gene promoter rs242557 and allele-specific protein binding (2011) (4)
Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. (1994) (4)
Multiple System Atrophy (2011) (4)
Differences in tau load are associated with different clinical phenotypes in progressive supranuclear palsy (2007) (4)
Dementia risk in Parkinson’s disease is associated with interhemispheric connectivity loss and determined by regional gene expression (2020) (4)
Treatment of writer's dystonia (1989) (4)
Crime and Parkinson's: The jury is out (2018) (4)
MOVEMENT-DISORDERS IN PSYCHIATRY (1990) (4)
Peptides in Neurological Diseases (1988) (4)
Stuttering, tic-like facial movements and behavioural disorders (2004) (4)
Wilson's disease: the 60th anniversary of Walshe's article on treatment with penicillamine. (2017) (4)
Encephalitis lethargica due to Epstein–Barr virus infection (2011) (4)
Endocrine aspects of bromocriptine therapy in Parkinsonism (2005) (4)
DIAGNOSIS OF PD. REPLY (1993) (4)
DA agonists ‐ Non‐Ergot derivaties: Apomorphine (2002) (4)
PISA SYNDROME IN PARKINSON'S DISEASE–A MOBILE OR FIXED DEFORMITY? (2013) (4)
Diagnosing social anxiety in Parkinson's disease: characteristics and frequencies according to two diagnostic criteria (2016) (4)
Deficit in a Krebs cycle mitochondrial enzyme in brains from patients with Parkinson's disease (2001) (4)
Noticing in neurology (2019) (4)
Dyskinesia: Research and Treatment. (Psychopharmacology/Supplementum 2.) (1986) (4)
Neuropathological progression of clinical Parkinson disease subtypes (2019) (4)
Clinical Heterogeneity in Cerebral Hemiatrophy Syndromes (2016) (4)
Original footage of the Chilean miners with manganism published in Neurology in 1967 (2015) (4)
Effects of L-deprenyl on parkinsonian bradyphrenia. (1990) (4)
Functional imaging of tremor in Parkinson's disease with [C-11]-WAY 100635 PET (2001) (4)
Clinical features of Progressive Supranuclear Palsy (PSP) in the United Kingdom (2001) (4)
Did Gustav Mahler have Sydenham's chorea? (2005) (4)
New version of the UPDRS: Development methods and working document for field testing (2005) (3)
Parkinsonism following electrical injury to the hand (vol 13, pg 600, 1998) (1998) (3)
Hyposmia in SWEDD (2015) (3)
The relationship between the First World War and neurology: 100 years of "Shell Shock". (2017) (3)
Behaviour provoked by simultaneous release ofdopamine and serotonin; possible relevance to psychotic behaviour (1980) (3)
Temporary deterioration in Parkinsonian signs after modest alcohol intake (1992) (3)
A biosketch of William Richard Gowers with a new review of his inpatient case history notes. (2013) (3)
Discovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing (2017) (3)
Testing the reflexes (2019) (3)
Dopamine dysregulation syndrome, impulse control disorders and subthalamic nucleus deep brain stimulation: A case series and literature review (2007) (3)
The Story of "Speed" from "Cloud Nine" to Brain Gain. (2015) (3)
Madopar HBS (hydrodynamically balanced system) in the treatment of Parkinson's disease. (1990) (3)
Multiple sclerosis leading to blepharospasm and dystonia in a sibling pair (1996) (3)
Intravenous apomorphine therapy in Parkinson's (2001) (3)
Managing advanced Parkinson's disease: the role of continuous dopaminergic stimulation (2007) (3)
Oral inhalation of apomorphine provides rapid rescue from 'off' periods in Parkinson's disease (PD): a phase 2a clinical study (2006) (3)
Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours (vol 134, pg 969, 2011) (2013) (3)
Pick’s disease with Pick bodies: An unusual autopsy case showing degeneration of the pontine nucleus, dentate nucleus, Clarke’s column, and lower motor neuron (2007) (3)
Neuroprotection and Natural History in Parkinson Plus Syndromes (NNIPPS): Design and progress report of a clinical trial of the efficacy and safety of riluzole in Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA) (2002) (3)
The neuropsychiatric complications of stimulant abuse (2015) (3)
A systematic review and meta-analysis of fracture risk in Parkinson's disease (2014) (3)
Subcutaneous apomorphine in Parkinson's disease (1989) (3)
Decades of delayed diagnosis in 4 levodopa‐responsive young‐onset monogenetic parkinsonism patients (2011) (3)
BROMOCRIPTINE AND THYROID-STIMULATING-HORMONE SECRETION (1977) (3)
Flickering Stimuli Do Not Reliably Induce Visual Hallucinations in Parkinson’s Disease (2019) (3)
Transplantation in Parkinson's disease. (1989) (3)
DA agonists ‐ Ergot derivaties: Lisuride (2002) (3)
Corrigendum to “Assessment of common variability and expression quantitative trait loci for genome-wide associations for progressive supranuclear palsy.” [Neurobiol. Aging 35 (2014) 1514.e1–1514.e12] (2015) (3)
Antiparkinsonian activity of L‐propyl‐L‐leucyl‐glycinamide or melanocyte‐inhibiting factor in MPTP‐treated common marmosets (2007) (3)
PARKIN DISEASE–A CLINICOPATHOLOGICAL ENTITY? (2013) (3)
Autonomic eVects of selegiline: possible cardiovascular toxicity in Parkinson's disease (1997) (3)
Association of MAPT haplotype-tagging SNPs with Parkinson's disease (2007) (3)
Vascular Dementia and Parkinsonism (2014) (3)
Sustained levodopa therapy in tardive dyskinesia. (1983) (3)
Erratum to “The analysis of C9orf72 repeat expansions in a large series of clinically and pathologically diagnosed cases with atypical parkinsonism” [Neurobiol. Aging 36 (2015) 1221.e1–1221.e6] (2015) (3)
Clinical grand round: A rapidly progressive pyramidal and extrapyramidal syndrome with a supranuclear gaze palsy (2005) (3)
Intravenous apomorphine therapy in Parkinson's (2001) (3)
Low prevalence of PANK2 mutations in Brazilian patients with early onset generalised dystonia and basal ganglia abnormalities on MRI (2010) (3)
Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naïve Parkinson's disease patients recently diagnosed with motor fluctuations (2020) (3)
Twenty Years of Apomorphine Therapy - How Does it Compare with Levodopa? Highlights of a Satellite Symposium Held at the 18th International Congress of Parkinson's Disease and Movement Disorders, Stockholm, 8-12 June 2014 (2014) (3)
Pisa syndrome in Parkinson's disease - A fixed deformity? (2013) (2)
Oligoclonal banding inthecerebrospinal fluid of patients withpostencephalitic Parkinsonism (1979) (2)
Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease. (2022) (2)
Parkinson's disease - 200 years: the outstanding contribution of "Old Hubert". (2017) (2)
Opicapone’s efficacy in Parkinson’s disease patients with motor fluctuations: a phase III, randomized, double-blind, placebo and active-controlled study – bipark I study (2015) (2)
One is always nearer by not keeping still (2015) (2)
On the Emergence of Tremor in Prodromal Parkinson's Disease. (2020) (2)
William Burroughs: Sailor of the Soul (2017) (2)
Slow Motion Analysis of Repetitive Tapping (SMART) test: measuring bradykinesia in recently diagnosed Parkinson's disease and idiopathic anosmia (2021) (2)
Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson’s Disease Patients with Motor Fluctuations (2022) (2)
Finding the grave of Sir William Richard Gowers (2017) (2)
Alzheimer pathology in Parkinson's disease (1989) (2)
Depression in Parkinson's disease is associated with impaired catecholamine terminal function in the midbrain, thalamus, and anterior cingulate cortex (2002) (2)
Neuronal filaments in Alzheimerʼs, Pickʼs, and Parkinsonʼs diseases (1987) (2)
EAN/MDS-ES Guidelines on pallidotomy for Parkinson´s disease: Let´s be accurate. (2022) (2)
Do Parkinson's Disease Patients Have Deficits in Sequential Sampling Tasks? (2014) (2)
Parkinsonism and dementia: Synucleinopathies, Tauopathies and Beyond (2003) (2)
Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study (2020) (2)
Endemic atypical parkinsonism (2018) (2)
JUVENILE-ONSET PARKINSONISM - SAME PATIENT REPORTED TWICE - REPLY (1992) (2)
One-year follow-up of opicapone's efficacy and safety in patients with Parkinson’s disease and motor fluctuations (BIPARK I) (2016) (2)
PATH50 Novelty-seeking and risk-taking behaviour in subtypes of Parkinson's disease (2010) (2)
Clinical and pharmacological aspectsof (-)-deprenyl treatment in Parkinson's disease (1983) (2)
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline disease severity: Post-hoc analysis from double-blind combined BIPARK-I and II data (2019) (2)
Down's syndrome and Parkinson's disease [letter] (1997) (2)
Maximising information on smell, quantitative motor impairment and probable REM-sleep behaviour disorder in the prediction of Parkinson’s disease (2020) (2)
Detecting tau isoforms in archival cases (2004) (2)
Functional MRI in multiple sclerosis: a simple motor task gives insights into a complex disease (2005) (2)
The more cortical amyloid‐β, the more postural instability in parkinson's disease: More grist to the mill for a link between walking, falling, and remembering? (2013) (2)
Reporting clinical trials: full access to all the data. (2002) (2)
ROPINIROLE - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF EFFICACY AND SAFETY AS ADJUNCT THERAPY IN PARKINSONIAN-PATIENTS WITH ON OFF FLUCTUATIONS (1993) (2)
PATU2 Novel truncation mutation of PRNP causes chronic diarrhoea, sensory neuropathy and autonomic failure associated with prion protein deposition in the cerebral blood vessels and small bowel (2010) (2)
Primary Progressive Aphasia With Parkinsonism (2013) (2)
Platelet phenolsulphotransferase activity in Parkinson's disease (2005) (2)
ON-OFF SYNDROME IN PARKINSON'S DISEASE AND INTRAVENOUS LEVODOPA (1982) (2)
TDP-43 proteinopathy in progressive supranuclear palsy (PSP) (2008) (2)
Selective peripheral denervation with posterior primary ramisectomy is useful for botulinum toxin resistant patients with cervical dystonia: Results of a prospective study (1999) (2)
Imaging serotonin HT1A binding in non-depressed and depressed Parkinson's disease patients with C-11-WAY100635 PET (2000) (2)
Patients' Postjudice of Tele‐Neurology for Movement Disorders (2022) (2)
The long-term outcome of impulsive compulsive behaviours in Parkinson’s disease (2019) (2)
Hypersexuality in Parkinson's disease (2007) (2)
Increased Alzheimer pathology in Parkinson's disease is associated with chronic antimuscarinic drug treatment (2002) (2)
Contents Vol. 45, 2001 (2001) (2)
Efficacy of opicapone in patients with Parkinson's disease with levodopa dose reduction: a pooled post-hoc analysis of BIPARK-I and II (2020) (2)
Fourth progressive supranuclear palsy (PSP–Europe) international medical workshop: Report on the fourth PSP–Europe international medical workshop (2004) (2)
1.278 Adult onset dystonic tremor as differential diagnosis for Parkinson's disease: Detailed clinical description of 20 patients emphasizing non-motor symptoms including olfactory function (2007) (2)
Opicapone as a levodopa sparing agent: Pooled analysis of BIPARK-I and II double-blind trials (2019) (2)
W R Gowers 1895: two unpublished post-graduate lectures. (2012) (2)
Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version (2007) (2)
Can Motor Features of Parkinson's Disease Be Used To Predict Occurrence of Non-Motor Symptoms of the Disease? (2010) (2)
European Academy of Neurology/Movement Disorder Society-European Section Guidelines on Pallidotomy for Parkinson's Disease: Let's Be Accurate. (2022) (2)
2.262 Adherence to antiparkinson medication in a multi-centre European study. (2007) (2)
Quality of life in Parkinson's disease at the Pan-European symposium in Marbella, May 24, 1997 (1998) (2)
Pooled safety and tolerability of opicapone in the treatment of Parkinson’s disease and motor fluctuations (2016) (2)
Optimising classification of Parkinson’s disease based on motor, olfactory, neuropsychiatric and sleep features (2021) (2)
Risk factors and early non-motor features for Parkinson's disease: A systematic review and meta-analysis (2012) (2)
ORAL DOPAMINE AGONISTS ADVERSE DRUG REACTION PROFILE (1999) (2)
Switching entacapone ‘non-responders’ to open-label opicapone: Change in absolute off-time following the 1-year extension BIPARK-I study (2019) (2)
Reporting clinical trials: full access to all the data (2001) (2)
NS 2330, a DA reuptake inhibitor, in levodopa-treated patients with Parkinson's disease and motor fluctuations: The Phase II ADVANS study (2006) (2)
New perspectives in non-oral drug delivery in Parkinson's disease: Highlights of a satellite symposium held at the XX world congress on Parkinson's disease and related disorders, Geneva, Switzerland, 8-11 December 2013 (2014) (2)
Parkinson’s disease with Onuf’s nucleus involvement mimicking multiple system atrophy (2009) (2)
Erratum: A functional polymorphism regulating dopamine β-hydroxylase influences against Parkinson's disease (Annals of Neurology (March 2004) 55 (443-446) DOI: 10.1002/ana.20235 (2004) (2)
Synucleinopathy with a G51D a-synuclein mutation: a neuropathological and genetic study (2013) (2)
Expanding the links between Brazilian and British neurology. (2010) (2)
Re-emergence of encephalitis lethargica-like syndrome: Evidence of CNS autoimmunity (2002) (1)
Imaging of movement disorders. Preface. (2010) (1)
In memoriam: Gerald malcolm stern (October 9, 1930-September 9, 2018). (2018) (1)
A CLINICAL AND PSYCHOPATHOLOGICAL STUDY OF GILLES-DE-LA-TOURETTE SYNDROME IN THE UNITED-KINGDOM (1987) (1)
Mutations in the GCH1 Gene Are Associated with Parkinson Disease (S17.001) (2014) (1)
ATYPICAL PARKINSONISM IN THE FRENCH WEST INDIES. AUTHORS' REPLY (1999) (1)
ATYPICAL PARKINSONISM IN THE FRENCH WEST INDIES. AUTHORS' REPLY (1999) (1)
DA agonists ‐ Ergot derivaties: Dihydroergocryptine (DHEC) (2002) (1)
An open label, single site, 12 month, phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (Exenatide) in the treatment of patients with moderate severity Parkinson's disease (2012) (1)
Ephedrone-induced Parkinsonism: Clinic-neuroimaging study (2007) (1)
GBA1 and LRRK2 mutations in higher and lower risk subjects from the PREDICT-PD project (2014) (1)
Reply: Lack of association between progressive supranuclear palsy and arterial hypertension: A clinicopathological study (2005) (1)
1.022 Adult onset dystonic tremor as differential diagnosis for Parkinson's disease: Detailed clinical description of 20 patients emphasizing non-motor symptoms including olfactory function (2007) (1)
Creutzfeldt Jacob disease presenting as progressive supranuclear palsy (2011) (1)
Pathological gambling in Parkinson's disease: An analysis of published case series (2007) (1)
Impulsive compulsive behaviours in patients with Parkinson's disease treated with dopamine agonists (2012) (1)
Small spiral, big mass (2018) (1)
Update on ephedrone induced parkinsonism with dystonia: Four year follow up (2012) (1)
Clinical applications of DaTSCAN (TM) and single photon emission tomography (SPET) (1999) (1)
Exenatide and non motor symptoms in Parkinson's disease (PD) (2014) (1)
Onset of drug-related adverse events in Parkinson's disease patients treated with opicapone in clinical practice: OPTIPARK post-hoc analysis (2020) (1)
Piribedil efficacy in monotherapy (150 to 300 mg/day) in de novo parkinsonian patients: A 6-month intermediate analysis of the 2-year Parkinson-Regain study (2004) (1)
Advice for those trying to find a cure for the shaking palsy (2018) (1)
Post‐streptococcal autoimmune dystonia with isolated bilateral striatal necrosis (2002) (1)
Is levodopa toxic? Insights from pathological studies. (2014) (1)
DA agonists ‐ Non‐Ergot derivaties: Pramipexole (2002) (1)
Dementia in Parkinsonism (2011) (1)
Design of a double-blind, placebo-controlled, phase-III trial in patients with Parkinson's disease and end-of-dose motor fluctuations: opicapone superiority vs. placebo (2012) (1)
William Walton Gooddy (2005) (1)
Progressive supranuclear palsy (PSP) studied withpositron emission tomography (PET) (1987) (1)
Classic diseases revisited Progressive supranuclear palsy (Steele-Richardson-Olszewski disease) (1999) (1)
Lithium: a slow burner (2020) (1)
Exenatide and motor symptoms in Parkinson's disease (PD) (2014) (1)
Observations on a 2-Step Approach to Screening for Parkinson Disease. (2017) (1)
Reply to 'Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study.' (2021) (1)
Visual hallucinations (2021) (1)
PD probability curves for smell tests: Interpreting smell test results in the diagnosis of Parkinson's disease (PD) (2008) (1)
“Flâneur neurologique in paris” – A guide to pinpointing the houses of famous neurologists in the late XIX century (2018) (1)
Chorea gravidarum: Another condition associated with Sydenham's chorea and antibasal ganglia antibodies (2004) (1)
The mechanism of slow axonal transport of the microtubule-associated protein tau and the transport rates of different isoforms and mutants (2002) (1)
Two-year results of the REGAIN study, a placebo-controlled trial with the non-ergot dopamine agonist piribedil as early treatment of Parkinson's disease (PD) (2005) (1)
Reporting clinical trials: full access to all the data (2002) (1)
Clinical Features of Vascular Parkinsonism in Pathologically Confirmed Cases (P06.074) (2012) (1)
Availability of olfactory bulb: experience from a British Brain Bank. (2013) (1)
Letter: Growth-hormone response to bromocriptine in parkinsonism. (1976) (1)
Reporting clinical trials: full access to all the data (2002) (1)
Re-emergence of encephalitis lethargica: New evidence of an autoimmune CNS disease (2002) (1)
Extrapyramidal signs in Parkinson’s disease. (1992) (1)
White matter involvement may explain phenotypic pleiotropy amongst genes involved in episodic movement disorders (2014) (1)
Adult onset dystonia can cause tremulous pseudoparkinsoniasm and is one cause of SWEDDs: Clinical description of 30 cases (2008) (1)
Early treatment of Parkinson's disease: Authors' reply. (1994) (1)
POMD01 Blinded analysis of conventional MRI in a cohort of pathologically confirmed parkinsonian illnesses (2010) (1)
A stimulus‐sensitive tic disorder characterized by echophenomena and coprolalia (2012) (1)
Striatal and extrastriatal PET measurements of dopa metabolism and D2 receptor status in patients with parkin gene mutations (2002) (1)
Clinicopathological comparison of globular glial tauopathies presenting with motor neuron disease or frontotemporal dementia: An emerging group of 4-repeat tauopathies (2011) (1)
Efficacy of opicapone in Parkinson’s disease patients according to baseline presence of dyskinesia: A post-hoc analysis from combined BIPARK-I and II (2019) (1)
Deletions at 22q11.2 in idiopathic Parkinson's disease: A combined analysis of GWAS data (2016) (1)
Treatment of the motor disorders of multiple system atrophy (2013) (1)
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline mao-b inhibitors use: Post-hoc analysis from double-blind combined BIPARK-I and II data (2019) (1)
Letters from Dom Pedro II to professor Brown-Séquard: imperial correspondence and neurophysiology. (2012) (1)
Prevalence of progressive supranuclear palsy (PSP) (Steele-Richardson-Olszewski syndrome) in the United Kingdom and creation of a national register (2000) (1)
Concerns Regarding Opicapone as Adjunct to Levodopa Therapy-Reply. (2017) (1)
Intranasal apomorphine: a novel treatment in Parkinson's disease (1990) (1)
DOPAMINERGIC FUNCTION IN RELATIVES OF PARKINSONS-DISEASE PATIENTS - A CLINICAL AND PET STUDY (1995) (1)
DA agonists ‐ Non‐Ergot derivaties: Piribedil (2002) (1)
The prevalence of progressive supranuclear palsy in the United Kingdom (2001) (1)
REM Sleep Behavior Disorder and Visual Hallucinations in a Pathologically Confirmed Case of Corticobasal Degeneration (2021) (1)
The primary olfactory cortex in Parkinson's disease (PD) and incidental Lewy body disease (ILBD) (2007) (1)
TAR DNA binding protein-43 (TDP-43) proteinopathy in association with progressive supranuclear palsy (2009) (1)
Frontotemporal lobar degeneration with FUS-positive inclusions (2010) (1)
The evolution of the acute response to L-dopa in Parkinson's disease (2002) (1)
Influence of disease severity in the efficacy response of Parkinson's disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II (2019) (1)
Patients with cervical dystonia thought to be secondary non responders to botulinum toxin treatment should be given a trial of EMG guided injections (2002) (1)
Switching entacapone or placebo to opicapone Open-label: Efficacy results of the BIPARK-I 1-year extension study (2017) (1)
Efficacy of opicapone in Parkinson’s disease patients according to baseline rasagiline use: A post-hoc analysis from combined BIPARK-I and II (2019) (1)
Clinical Neuropathologic Correlation (2010) (1)
In memoriam - Macdonald Critchley 2nd January 1900 15th October 1997 Bristol Nether Stowey (1998) (1)
C. David Marsden - (April 15, 193-September 29, 1998) - In memoriam (1999) (1)
Gabriel Garcia Marquez, the greatest of the amnesia writers (2022) (1)
Intermittent Apomorphine Use for off Period Rescue in Parkinson's Disease: A Pragmatic Review of over Three Decades of Clinical Experience (2022) (1)
MATTERS ARISING (1994) (1)
In search of Charcot's second sight (2021) (1)
The Early Treatment Phase in Parkinson's Disease: Not a Honeymoon for All, Not a Honeymoon at All? (2023) (1)
Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: A post-hoc analysis from combined BIPARK-I and II (2019) (1)
O2-02-02 The H1c risk haplotype of the MAPT gene is over-expressed in human temporal cortex relative to the other common alleles of MAPT (2006) (1)
P3-161 Increased MAPT expression is associated with progressive supranuclear palsy (2006) (1)
PLASMA AND CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN CORRELATE IN ATYPICAL PARKINSONIAN SYNDROMES AND DISTINGUISH THEM FROM PARKINSON’S AND ALZHEIMER’S DISEASE (2017) (1)
Chronic effects of inflammation on tauopathies (2023) (1)
Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Patient and clinical global impression of change from the BIPARK-I double-blind experience (2019) (1)
Tdap Vaccination Rates in Pregnant Women at UCLA: Impact of In-Office Vaccine Availability (2015) (1)
JUVENILE-ONSET PARKINSONISM : SAME PATIENT REPORTED TWICE. AUTHOR'S REPLY (1992) (1)
Brain monoaminergic innervation in Parkin patients: A PET study (2006) (1)
Intrathoracic Malignancy Mimicking Axial Dystonia (2016) (1)
A Brazilian Football Player Still on the Pitch After 10 Years of Parkinson's Disease with Severe Freezing of Gait (2015) (1)
Neuropsychiatric inventory (NPI) useful instrument in dopamine dysregulation syndrome (DDS) (2008) (1)
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline dopamine agonist use: Post-hoc analysis from double-blind combined BIPARK-I and II data (2019) (1)
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to gender: Post-hoc analysis from double-blind combined BIPARK-I and II data (2019) (1)
Farewell from the outgoing editors (2004) (1)
Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson's disease patients: Post-hoc analysis from combined BIPARK-I and II (2019) (1)
[I-12]-FP-CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor. (vol 53, pg 489, 2003) (2003) (1)
Anxiety and depression in PSP: Common, but unrelated to disease severity (2002) (1)
Gilles de la Tourette's Syndrome Centenary Symposium (1985) (1)
Incidence of treatment-emergent adverse events in Parkinson's Disease patients according to baseline body mass index: Post-hoc analysis from double-blind combined BIPARK-I and II data (2019) (1)
Progressive parkinsonism, oculomotor abnormalities and autonomic dysfunction: Clinicopathological case (2011) (1)
Concomitant progressive supranuclear palsy and chronic traumatic encephalopathy in a boxer (2014) (1)
Catechol-0-methyl transferase inhibitors in the treatment of Parkinson's disease. (1998) (1)
Hemichoreo‐hemibalism as a Manifestation of Central Nervous System Chronic Graft‐versus‐Host Disease (2017) (1)
PRRT2 related paroxysmal kinesigenic dyskinesia (PKD) (2013) (0)
Impact of 3-month earlier versus later initiation of opicapone versus entacapone in levodopa-treated patients with Parkinson's disease and motor fluctuations (2021) (0)
Progressive Supranuclear Palsy Quality of Life Scale (2020) (0)
Developing a better UPSIT for PD (2010) (0)
John Michael Walshe (April 24, 1920-October 14, 2022). (2023) (0)
Measuring quality of life in progressive supranuclear palsy: The PSP-QoL (2011) (0)
The nature of failing in progressive supranuclear palsy (2004) (0)
Opicapone in clinical practice in Parkinson's disease UK patients with motor fluctuations: Findings from the OPTIPARK study (2021) (0)
Neuropathology of primary dystonia unrelated to DYT1 mutations (2007) (0)
East meets west to provide the best for PD patients (2012) (0)
Gowers and clinical diagnosis (2012) (0)
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of safinamide: Findings from the real-world OPTIPARK study (2021) (0)
BRAIN Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson’s disease (2012) (0)
CJN volume 29 issue 1 Cover and Front matter (2002) (0)
Opicapone in clinical practice in Parkinson's disease German patients with motor fluctuations: Findings from the OPTIPARK study (2021) (0)
Clinical and pathological features of frontotemporal lobar degeneration with FUS-positive inclusions (2010) (0)
Reporting Clinical Trials: Full Access to All the Data (2001) (0)
A comprehensive diagnostic test for familial and early onset Parkinson's disease based on next-generation sequencing (2012) (0)
Perturbed glucose metabolism in Parkinson's disease (2014) (0)
Influence of disease duration on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study (2021) (0)
Parkinsonism before James Parkinson: The “Marília de Dirceu” Case (2022) (0)
Event-related potentials in the early stages of Parkinson's disease - A cautionary tale (1996) (0)
Reply to letter: multiple system atrophy‐parkinsonism with slow progression and prolonged survival: A diagnostic catch (2013) (0)
Nigrostriatal dysfunction in parkin linked parkinsonism and asymptomatic heterozygous carriers: A progressive study with 18-dopa pet (2008) (0)
DA agonists ‐ Ergot derivaties: Bromocriptine (2002) (0)
1.IS.2. Rasagiline - optimising treatment outcomes throughout the progression of PD (Teva/Lundbeck) (2007) (0)
Sensorimotor re-organisation is different in musicians dystonia and writers cramp (2006) (0)
Tricks of the trade. (2012) (0)
Olfactory Loss in LRRK2 Related Parkinsonism (2010) (0)
Dopamine transporter imaging with I-123-FP-CIT SPECT demonstrates marked presynaptic nigrostriatal dopaminergic deficit in orthostatic tremor (2002) (0)
Reporting clinical trials: full access to all the data (2002) (0)
Reporting clinical trials: Full access to all the data (2002) (0)
Dermentia in Parkinsonism (1997) (0)
A NEW TIC-BORNE MYELOPATHY? (2009) (0)
‘Grand old man’ of clinical neurology (2012) (0)
123 I-FP-CIT SPECT in the confirmation of organic parkinsonism (1999) (0)
Oligodendrocyte precursor cells do not contain pathological inclusions in multiple system atrophy or progressive supranuclear palsy (2010) (0)
P08.9 Loss of the orbicularis oculi acoustic blink and startle reflexes in progressive supranuclear palsy (2006) (0)
Bird watching on the asphalt. (2021) (0)
2 Movement disorders – the parkinson’s névrose (2017) (0)
Thanks to Editorial Board of Arquivos de Neuro-Psiquiatria (2022) (0)
Dopamine devils. (2021) (0)
Phenylactic acid inhuman body fluids: high correlation between plasma and cerebrospinalfluid concentration values (1982) (0)
How do G51D SNCA mutation cases compare clinically and neuropathologically to SNCA duplication and H50Q SNCA mutation (2014) (0)
The role of mendelian PD genes in non-mendelian PD: A haplotype tagging approach (2004) (0)
61. Analysis of 123I-FPCIT (DATSCANTM) binding in normal volunteers and in patients with Parkinsonʼs disease (2002) (0)
The accuracy of clinical diagnosis of tremor dominant Parkinson's disease in a specialist hospital setting: A blinded videotape study (2009) (0)
Switching from double-blind entacapone or placebo to open-label opicapone: UPDRS-II and III results from patients who ended 1-year BIPARK-I extension on opicapone 50 mg (2019) (0)
Hidden in plain sight: a rationale for repurposing apomorphine in addiction disorders (2020) (0)
Clinical and neuropathological features of synucleinopathy associated with G51D SNCA mutation (2013) (0)
Neurophysiological characterisation of myoclonus dystonia (2006) (0)
POSITRON EMISSION TOMOGRAPHIC ASSESSMENT OF STRIATAL OPIOID RECEPTOR DENSITY IN TOURETTES-SYNDROME AND HUNTINGTONS-DISEASE (1994) (0)
A Clinicopathological Study of a Case of Parkinson's Disease (2010) (0)
Magnetic resonance spectroscopy of patients with Wilson's disease (2001) (0)
Genome-wide association analysis of Dementia with Lewy bodies reveals unique genetic architecture (2017) (0)
MATTERS ARISING (1995) (0)
Novel method for quantification of 3R-and 4R-tau isoforms in the cerebrospinal fluid of patients with atypical parkinsonian syndromes (2012) (0)
Editorial (2003) (0)
LRRK2 ASSOCIATED PARKINSON'S DISEASE: CLINICAL FACTORS BASED ON WORLDWIDE EXPERIENCE (2009) (0)
Sir William Osler's 'Influences' for the Successful Physician, A Reappraisal After 126 Years. (2018) (0)
Identifying genetic risk factors for idiopathic Parkinson's disease by combining genome-wide copy number variation data and published data from genome-wide sib-pair linkage studies (2006) (0)
21 Psychedelic treatment of functional neurological disorder – a systematic review (2020) (0)
Phenomenological study of Parkinsonism in the French West Indies (1999) (0)
144 Studying corticobasal syndrome across the UK via the BNSU (2019) (0)
Definition of the tau gene haplotype block that is associated with progressive supranuclear palsy (2004) (0)
Parkinson ' s disease . previously untreated patients with Sustained bromocriptine therapy in (0)
The on-off effect - a side-effect of long-term levodopa treatment. (1978) (0)
Tremor - Basic mechanisms and clinical aspects - A symposium of the Movement Disorder Society held in Kiel, Germany, on July 11-12, 1997 (2000) (0)
Using the 16 item identification test from Sniffin Stick's (SS-16) in the diagnosis of Parkinson's disease (PD) in Sri Lanka (2008) (0)
Impulse control disorders in Parkinson's disease are associated with increased sleep disturbance (2009) (0)
Handbook of Tremor Disorders (1995) (0)
Ophthalmic pathology and visual hallucinations (VH) in PD (2010) (0)
Novel Truncation Mutation of PRNP Causes Chronic Diarrhoea, Sensory Neuropathy and Autonomic Failure Associated with Prion Protein Deposition in the Cerebral Blood Vessels and Small Bowel (2010) (0)
Influence of levodopa daily dose on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study (2021) (0)
14.57 Expanding the phenotypic spectrum of PSP: Findings from the PROSPECT-UK study (2019) (0)
Blinded analysis of conventional MR images in a cohort of pathologically confirmed parkinsonian illnesses at the QSBB (2010) (0)
15th Annual Scientific Meeting of the Clinical Autonomic Research Society (2005) (0)
The Importance of Steady-State Plasma Dopa Levels in Reducing Motor Fluctuations in Parkinson's Disease (2008) (0)
Investigation of the microtubule associated protein tau locus (2004) (0)
Comprehensive genetic investigation of NBIA and complex dystonia-parkinsonism (2012) (0)
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of dopamine agonists: Findings from the real-world OPTIPARK study (2021) (0)
Rewiring MIR retrotransposons in long non-coding RNAs to regulate translation of paired antisense genes: the case of MAPT-AS1 (2018) (0)
Neuroacanthocytosis: genetic, clinical, and pathological follow-up of a case series (2007) (0)
Clinicopathological features of patients with multiple system atrophy with a family history of Parkinson's disease (2006) (0)
A rare cause of L-Dopa responsive parkinsonism: The answer lies in the eyes (2011) (0)
Symptoms and treatment of Alzheimer's disease. (1988) (0)
Thanks to Editorial Board of Arquivos de Neuro-Psiquiatria (2021) (0)
DA agonists ‐ Overview (2002) (0)
Lack of association between progressive supranuclear palsy and arterial hypertension : A clinicopathological study. Authors' reply (2005) (0)
Contents Vol. 69, 2013 (2013) (0)
Parkinson's disease mimicking multiple system atrophy, with involvement of Onuf's nucleus (2007) (0)
Comparison of depression, anxiety and quality of life in PSP and MSA (2009) (0)
Oral session XIV: Parkinson's disease (2004) (0)
Detection of non-motor symptoms in Parkinson's disease and impact on health-related quality of life (2008) (0)
Acknowledgment to reviewers (1999) (0)
CAMPTOCORMIA: WHAT IS THE CAUSE? (2012) (0)
A systematic, comprehensive, blinded radiological study of MR findings in pathologically confirmed PSP, MSA and PD (2009) (0)
Botulinum toxin A (2022) (0)
Reply (2000) (0)
Obituary for Dr. John C. Steele (1934-2022). (2022) (0)
Diagnostic accuracy in 18 cases of pathologically confirmed corticobasal degeneration (2009) (0)
Availability of olfactory bulb and olfactory tract in brain specimens in a brain bank (2012) (0)
The relation between dementia and direct involvement of the hippocampus and amygdala in PD (1998) (0)
PO086 European registry of corticobasal degeneration a prospect sister study: recruitment of patients with corticobasal syndrome via the bnsu (2017) (0)
Dopamine dysregulation syndrome, impulse control disorders and subthalamic nucleus deep brain stimulation: two cases and literature review (2008) (0)
Subject Index Vol. 45, 2001 (2001) (0)
Measuring Severity of Impulse Control Disorders in Parkinson's Disease Using Objective Validated Questionnaire (2010) (0)
Multiple roles for TDP-43 in tau gene expression regulation (2012) (0)
P2-174: Expression of three-repeat and four-repeat tau isoforms and mRNA levels in control and progressive supranuclear palsy brains (2008) (0)
Clinicopathological study of progressive supranuclear palsy presenting with corticobasal syndrome (2012) (0)
Impulse Control Disorders Subtypes in Parkinson's Disease: Clinical and PET Correlations (2010) (0)
Two Decades of Evolving Care with Pump Therapies – What have we Learned? (2012) (0)
Opicapone in clinical practice in Parkinson's disease patients with motor fluctuations: findings from the OPTIPARK study (2020) (0)
BOOK REVIEWS (1991) (0)
Acknowledgment of reviewers (1997) (0)
THE BRADYKINESIA–AKINESIA INCOORDINATION TEST: A SIMPLE OBJECTIVE TEST IN MULTIPLE SCLEROSIS (2013) (0)
The case of the locked house (2013) (0)
Transcriptional differences in putaminal tissue of individual MSA-P and PD cases (2005) (0)
Is the brain-derived neurotrophic factor (BDNF) Val66Met genetic polymorphism associated with impulsive-compulsive behaviours in Parkinson's disease? (2012) (0)
The spectrum of pathological involvement of multiple system atrophy (MSA): clinicopathological correlations (2005) (0)
1115 Chronic traumatic encephalopathy in retired footballers with dementia (2017) (0)
Picturing the atrophy patterns of progressive supranuclear palsy and multiple system atrophy in vivo using fluid registered MRI (2003) (0)
Using the anterior olfactory nucleus to study lewy pathology in olfactory structures (2013) (0)
Lewy bodies in surviving transplanted neurons indicate host-to-graft propagation of Parkinson's disease pathology (2009) (0)
A combined case of tauopathy and Alpha-synucleinopathy (2007) (0)
Phenotypic variability in PSP: Unbiased analysis of serial MRI (2006) (0)
Prominent neurolibrillary tangle pathology in a Parkin brain (2002) (0)
A five-year review of treatment and research on spasmodic dysphonia (1995) (0)
PREDICT-PD study: Online screening algorithm identifying Parkinson's disease risk (2013) (0)
Medical student 1863–70 (2012) (0)
USE OF AMPHETAMINE AT HIGH DOSAGE IN THE STUDY OF DA-5HT INTERACTIONS - EFFECTS OF NEUROLEPTICS (1980) (0)
YAWNING IN PARKINSON'S DISEASE. AUTHORS' REPLY (1999) (0)
Reply (2012) (0)
Objective decrement in Parkinson's disease - A new parameter for the BRAIN tap test (2016) (0)
Drugs to treat urinary frequency, urgency, and/or urge incontinence (2002) (0)
P4-035 Melanized nigral neurons in Caucasians and Africans (2004) (0)
Davunetide for progressive supranuclear palsy: Results of the AL-108-231, phase 2/3, 52 week, multi-center, randomized, double-blind, placebo-controlled clinical trial (2013) (0)
Investigating the genetic architecture of Dementia with Lewy bodies: a genome-wide association study (2018) (0)
Differences in the disordered sensorimotor organisation of the hand in musician's dystonia and writer's cramp: Clue for different pathophysiology? (2004) (0)
Olfaction in progressive supranuclear palsy (PSP) (2009) (0)
Cognitive impairment in multiple system atrophy: a clinico-pathological study (2013) (0)
Editorial (2001) (0)
Punding in Parkinson's Disease Questionnaire (2016) (0)
Regional expression of alpha-synuclein in multiple system atrophy (2013) (0)
European Academy of Neurology/Movement Disorder Society-European Section´s Guidelines on pallidotomy for Parkinson´s disease: Let´s remain accurate. (2022) (0)
Co-morbid impulse control disorders in Parkinson's disease (2014) (0)
Thromboembolic complications in children and adolescents: who is at risk? (1995) (0)
Clinical presentation of SWEDDS with abnormal olfaction (2010) (0)
Editorial (1996) (0)
Opicapone odds ratio in relative off-time reduction: A post-hoc analysis from combined BIPARK-I and II data (2019) (0)
Failure to identify change in the cervical dystonia muscle pattern is the main cause of reduced response to BTXA (2003) (0)
Controlled trial of speech therapy and intra-parotid botulinum toxin for the treatment of salivary drooling in Parkinson's disease (2002) (0)
Depression Leading to Attempted Suicide After Bilateral Subthalamic Nucleus Stimulation for Parkinson’s Disease (2002) (0)
Archive(s) (2020) (0)
Extrapyramidal Disorders. Journal of Neural Transmission Supplementum 19 (1984) (0)
Encouraging a Generation of Tremor Researchers: Macdonald Critchley's Paper on Essential Tremor (2021) (0)
The clinical features of African-Brazilian patients with Parkinson's disease (2009) (0)
Reply: MRI findings of visual system alterations in Parkinson's disease. (2017) (0)
Patients with adult onset dystonic tremor and scans without evidence of dopaminergic deficit (SWEDDs) resembiling tremulous Parkinson's Disease: A comparative analysis of 21 cases (2008) (0)
Somatic Mitochondrial DNA Mutations and Parkinsonism Reply (2012) (0)
Switching from double-blind entacapone or placebo to open-label opicapone: change in OFF-/ON-time from patients who ended the 1-year BIPARK-I extension on opicapone 50 mg (2019) (0)
Sleep Disturbance, Dreams, Mood and Impulsive-Compulsive Behaviours in Parkinson's Disease (2010) (0)
Development of an ELISA for sensitive quantification of three-repeat and four-repeat tau isoforms in tauopathies and characterisation of tau isoforms in CSF (2006) (0)
Movement disorder in Whipple's disease (2001) (0)
Clinical characteristics of patients with visual hallucinations (VH) in PD (2010) (0)
Clinico- Demographical Correlations of Dementia in Pathologically Confirmed PD (2010) (0)
First stage association analysis of neuropatholically proven PD confirms MAPT as an independent risk factor for PD (2012) (0)
The prevalence of impulsive compulsive behaviors in patients treated with apomorphine infusion: a retrospective analysis (2020) (0)
Two year follow up in ephedrone induced parkinsonism with dystonia (2009) (0)
Authors' reply (1994) (0)
Information sampling in drug naive patients with Parkinson's disease (2014) (0)
Correlation between punding and dyskinesias in Parkinson's disease (PD) (2005) (0)
The accuracy of clinical diagnosis of multiple system atrophy: an application with gray cases and true negative cases (2004) (0)
Gowers 1895 : two unpublished post-graduate lectures (2012) (0)
Genetics of progressive supranuclear palsy. (2008) (0)
Muscarinic receptors in the frontal cortex in progessive supranuclear plasy (2006) (0)
119 A pilot study of an algorithm designed to identify Parkinson's disease in the early, non-motor phase (2011) (0)
Strong association of novel tau promoter polymorphisms with progressive supranuclear palsy (2000) (0)
Myoclonus associated with long-standing poliomyelitis is due to central reorganization (2004) (0)
Tolcapone as an alternative to entacapone for adjunctive therapy in Parkinson's disease: An evidence-based efficacy comparison (2007) (0)
Parkinson's dis e (2002) (0)
performance . levodopa and motor absorption of intraduodenal The effects of oral protein on the (0)
Off- and on-time responder post-HOC analyses of pooled opicapone phase III studies (2017) (0)
Lewy-and Alzheimer-type pathologies in Parkinson's disease with dementia: A comprehensive brain-bank study (2010) (0)
Movement disorders offers electronic manuscript submission (2003) (0)
Issue Information (2022) (0)
Gowers: the man, his work, and his legacy (2012) (0)
Superior cerebellar peduncle volume measurement on MRI differentiates progressive supranuclear palsy (PSP) from multiple system atrophy (MSA), Parkinson's disease (PD) and controls (2004) (0)
Low prevalence of PANK2 mutations in Brazilian cases of neurodegeneration with brain iron accumulation (2007) (0)
Editorial (2001) (0)
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of entacapone: Findings from the real-world OPTIPARK study (2021) (0)
Genetics of the tau locus in progressive supranuclear palsy (2002) (0)
PNL4 NEW LEVODOPA/CARBIDOPA/ENTACAPONE (STALEVO®) RESULTS IN BETTER QUALITY OF LIFE FOR PARKINSON'S DISEASE PATIENTS AND SAVES COSTS TO THE SOCIETY (2004) (0)
[Neuropsychological disorders in Parkinson disease. Relations to psychomotor inhibition and obsessive-compulsive disease]. (1989) (0)
Drugs to treat gastrointestinal motility problems (2002) (0)
Opicapone in clinical practice in Parkinson's disease patients with motor fluctuations and complications of therapy at baseline: Findings from the OPTIPARK study (2021) (0)
Genetic analysis on six Brazilian families with dopa responsive dystonia. (2007) (0)
Parkinsonism without Pathological Abnormality (2011) (0)
Parkinson ' s disease . receptor sensitivity in patients with motor performance and dopaminergic The effects of acute levodopa withdrawal on (0)
THE NATURE OF APRAXIA IN CORTICOBASAL DEGENERATION - REPLY (1994) (0)
The pathological basis of disproportionate antecollis in multiple system atrophy (2005) (0)
of Parkinson ' s disease . Subcutaneous apomorphine in the treatment (0)
THE NOSOLOGY OF PARKINSON'S DISEASE (2011) (0)
Alteration in alpha synuclein gene transcription Parkinson's disease. (2000) (0)
GLOBULAR GLIAL TAUOPATHIES: AN EMERGING GROUP OF 4-REPEAT TAUOPATHIES PRESENTING WITH MOTOR NEURON DISEASE OR FRONTOTEMPORAL DEMENTIA (2011) (0)
Title Page Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study. Authors in order: (2011) (0)
Akathisia and Restless Legs. By P. Sachdev. (Pp. 425; £45.00.) Cambridge University Press: Cambridge. 1995. (1998) (0)
Antiparkinsonian drugs and visual hallucinations – Authors' response (2006) (0)
Attention tea action in Parkinson's disease (2001) (0)
Disequilibrium in MSA phenotype distribution between populations: genetics or environment? (2010) (0)
Will the Real James Parkinson Please Stand Up? Another Fake James Parkinson (2019) (0)
Certain tremor parameters can differentiate PD tremor from pseudoparkinsonian tremor in patients with normal DAT scans (SWEDDs) (2008) (0)
Early diagnosis of Parkinson's disease. (1981) (0)
the treatment ofParkinson's disease (0)
Melanized nigral neurons in caucasians and Africans (2004) (0)
THE CLINICAL AND PATHOLOGICAL FEATURES OF CORTICAL LEWY BODY DISEASE (1986) (0)
Apomorphine infusions for treatment of advanced Parkinson's disease (2001) (0)
CLINICOPATHOLOGICAL OBSERVATIONS IN MULTIPLE SYSTEM ATROPHY - REPLY (1992) (0)
Increased MAPT expression as the possible functional basis of the genetic association with PSP (2006) (0)
Parkinsonism without pathological explanation (2011) (0)
The PSP QoL (PSP-QoL): A validated, patient-based outcome measure for progressive supranuclear palsy (2005) (0)
EARLY TREATMENT OF PARKINSONS-DISEASE - REPLY (1994) (0)
Authors' reply (1996) (0)
P2-155 Development of sensitive and specific ELISAs for three-repeat and four-repeat tau isoforms (2006) (0)
A beta and alpha-synuclein pathologies in Parkinson's disease (2007) (0)
Progressive supranuclear palsy (PSP) with prominent corticospinal tract degeneration in motor neuron disease (MND) (2010) (0)
Increased BMI May Protect against Parkinson's Disease: Evidence From Mendelian Randomisation Study (2017) (0)
Clinical and electrophysiological criteria to differentiate patients with dystonic tremulous pseudo-parkinsonism from tremor-dominant Parkinson's disease (2008) (0)
Botulinum Toxin B for patients with oromandibular dystonia resistant to Botulinum Toxin A: Report of four cases (2004) (0)
C9orf72 expansion in atypical parkinsonism (2013) (0)
A clinicopathological study of parkin-linked parkinsonism - A study of 5 cases and comparison with Parkinson's disease (2012) (0)
Our Unforgettable Case of Malignant Motor Fluctuations in a Parkinson Patient (2012) (0)
120 An algorithm to identify individuals at high-risk of Parkinson's disease in the community (2012) (0)
Light and Shade in Patrick Lewis et al's Paper on the First Photographs of Parkinson's Disease (2020) (0)
Detection of Subclinical Cases Using 18 F-Dopa and 18 Fluorodeoxyglucose Positron Emission Tomography (2016) (0)
The antiparkinsonian activity of L-Propyl-L-Leucyl-Glycinamide (PLG) or Melanocyte-Inhibiting Factor (MIF) in MPTP-treated common marmosets (2006) (0)
P3-306 Differential distribution of tau protein isoforms in sporadic FTLD and FTDP-17 (2006) (0)
502: Queen Square, Richardson, Robertson and PSP before 1964 (2008) (0)
Parkinson-Specific Motor and Mental Disorders — Role of the Pallidium: Pathophysiological, Biochemical and Therapeutic Aspects, R. G. Hassler, J. F. Christ (Eds.), in: Advances in Neurology, Vol. 40. Raven Press (1984), xxxii + 579, ISBN: 0 890 04940 8 (1984) (0)
Life Outside Work (2012) (0)
Slow Motion Analysis of Repetitive Tapping (SMART) Test: Measuring Bradykinesia in Recently Diagnosed Parkinson's Disease and Idiopathic Anosmia. (2021) (0)
Smell loss and diet changes in Parkinson's disease (2011) (0)
Frontotemporal lobar degeneration with ubiquitin-only-immunoreactive neuronal changes presenting with the clinical phenotype of progressive supranuclear palsy (PSP) (2005) (0)
Defining the pathology underlying cortico-basal syndrome: A European study (2016) (0)
Clinical features of patients with pathology confirmed vascular parkinsonism (2002) (0)
Gower's Queen Square case notes on chorea (2012) (0)
The Spectrum of FUS-Positive Pathology in Frontotemporal Lobar Degenerations (2010) (0)
Gint aneurysm of the petrous portion of the carotid artery (0)
Atypical parkinsonism in the French West Indies (1999) (0)
Regular dopaminergic therapy cross-sensitises to the effects of methylphenidate (2005) (0)
Reply to Moghal S and Rajput AH, on clinicopathological observations in multiple system atrophy and Parkinson’s disease (1992) (0)
ALTERATIONS IN IRON CONTENT IN PARKINSONIAN BRAIN (1988) (0)
Two cases of abnormal dopamine transporter scan in chorea-acanthocytosis (2014) (0)
BRADYPHRENIA IN PARKINSONS-DISEASE AND PSYCHOMOTOR RETARDATION IN DEPRESSION - AN EXPERIMENTAL-STUDY (1987) (0)
Diffusion weighted MRI differentiates MSA-P from PSP (2006) (0)
VBM as a tool to identify regions which may aid differential diagnosis of PSP, PD and MSA using MRI (2004) (0)
Improving estimation of Parkinson’s disease risk—the enhanced PREDICT-PD algorithm (2021) (0)
Influence of baseline off-time in the efficacy response of Parkinson's disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II (2019) (0)
CORTICOBASAL SYNDROME AND CORTICOBASAL DEGENERATION (2016) (0)
Final, 14-year follow-up of the randomized, controlled PDRG trial comparing three treatments in de novo Parkinson's disease (2004) (0)
Sensorimotor organisation of the hand area is differently modulated by proprioceptive training in musician's dystonia and writer's cramp (2007) (0)
Does Levodopa Affect Progression of Neuropathology in Parkinson's Disease? A Clinico-Pathological Study (2010) (0)
Neuropathology of primary adult onset non-DYT1 dystonia (2008) (0)
Family and schooling in Victorian England (2012) (0)
Differences in atrophy on MRI and voxel-based morphometry in progressive supranuclear palsy (PSP) and Parkinson's disease (PD) (2004) (0)
Slowly progressive L-dopa responsive parkinsonism with neurofibrillary tangle pathology: A new clinicopathological entity? (2014) (0)
141 Switching from double-blind entacapone or placebo to open-label opicapone: NMSS results (1-year extension BIPARK-I study) (2019) (0)
1 Soulful neurology (2020) (0)
BROMOCRIPTINE FOR PARKINSON’S DISEASE (1978) (0)
The visual estimation of midbrain to pons ratio combined with cerebrospinal fluid biomarkers improves the diagnostic accuracy of PSP (2015) (0)
Authors' reply (1996) (0)
Dorsal column grey matter an essay on the shaking palsy (2017) (0)
Backward walking and circling: a behavioural response to concurrent catecholamine and 5-hydroxytryptamine release [proceedings]. (1979) (0)
Editorial (1996) (0)
Dissection of tau isoform composition of tauopathy lesions using novel isoform-specific monoclonal antibodies (2002) (0)
Tourette ' s syndrome . postsynaptic dopaminergic system in PET studies of the presynaptic and (0)
Multiple system atrophy - Reply (vol 53, pg 212, 1996) (1996) (0)
Can handwriting distinguish dystonic pseudoparkinsonism front Parkinson's disease? (2009) (0)
TICS (1996) (0)
Does L-dopa have toxic effects in Parkinson's disease brain? (2009) (0)
OPL081 Visual hallucinations are specific for lewy body parkinsonism and improve diagnostic accuracy: a clinicopathological study (2005) (0)
Replies to ‘Romberg's sign no longer stands up’ (2016) (0)
[Apomorphine in the treatment of Parkinson's disease]. (1990) (0)
202: Severity of tau deposition in progressive supranuclear palsy is associated with clinical phenotype (2008) (0)
Decision-making, impulsivity and behavioural addictions: Do Parkinson's patients jump to conclusions? (2012) (0)
Parkinsonism Carers Quality-of-Life Instrument (2017) (0)
The pathological substrate for clinically diagnosed Parkinson's disease (2010) (0)
Influence of demographic characteristics in the efficacy response of Parkinson’s disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II (2019) (0)
Tau in progressive supranuclear palsy-parkinsonism and Richardson's syndrome (2008) (0)
114th Meeting of the British Neuropathological Society Institute of Child Health, London  Symposium: ”Advances in Motor Neuron Diseases” 13th March 2013 (2013) (0)
Oral presentations (2014) (0)
Oscillations in the performance in levodopa treated parkinsonians. (1980) (0)
The anatomy of the midbrain including the subthalamic nucleus and substantia nigra as seen using high field MRI at 9.4 Tesla: Preliminary work involving correlation of MR and histopathological images (2008) (0)
To the Editor (1990) (0)
De Lange's syndrome. Nursing care study. (1978) (0)
John Michael Walshe – Born 24 April 1920, Died 14 October 1922 (2023) (0)
The importance of steady state blood dopa levels in reducing motor fluctuations (2007) (0)
Dyskinesia: Research and Treatment. (1986) (0)
Optimizing olfactory testing for the diagnosis of Parkinson’s disease: item analysis of the university of Pennsylvania smell identification test (2018) (0)
Examination of a proposed method for the identification and estimation of oils and fats (0)
Akathisia and restless legs. (1998) (0)
Dementia in dementia with Lewy bodies may not be attributable to Alzheimer pathology (2004) (0)
Turning Back the Clock in Parkinson's Disease: Practical Recommendations for Managing Diurnal Symptom Worsening. (2021) (0)
The magic of L-dopa (2007) (0)
Exome sequencing in familial multiple system atrophy (2012) (0)
Increased dopamine neurotransmission in Parkinson's patients with Impulse control disorders in response to rewarding visual stimuli: A pilot study (2009) (0)
Pathological mysteries of PD (2005) (0)
[Some reflections on the lasting importance of James Parkinson's Essay on the Shaking Palsy]. (2018) (0)
Chronic manganism clinical features and causes (2010) (0)
Primary immunodeficiency (PP-051) (2010) (0)
THE MANAGEMENT OF TICS (1988) (0)
La Folie des Grandeurs. (2020) (0)
Parkinsonism and dementia: Synucleinopathies, tauopathies and beyond - Introduction (2003) (0)
La Folie des Grandeurs. (2020) (0)
Le Bal des Folles (2022) (0)
Conférence : Protéine tau et syndromes parkinsoniens (2002) (0)
Book Review His last bow. (2019) (0)
R. G. Hassler J. F. Christ (1984) (0)
BOOK REVIEWS (1991) (0)
Charcot's capricious scribe. (2019) (0)
3.422 The effect of motor fluctuations on Parkinson's disease patient Quality of Life and the potential benefits of apomorphine continuous infusion (2007) (0)
Book Review His last bow. (2019) (0)
Editorial farewell. (1993) (0)
Senior moments (2021) (0)
Response from the editors (2006) (0)
Charcot's capricious scribe. (2019) (0)
Obituary: John Robert Stubbs (1953) (0)
Charcot's capricious scribe. (2019) (0)
Book Review His last bow. (2019) (0)
Choice of treatment in Parkinson's disease. (1977) (0)
Editorial (1996) (0)
Charcot's capricious scribe. (2019) (0)
Apprentice year 1863 (2012) (0)
A decade of delayed diagnosis in two cases of monogenetic parkinsonism (2010) (0)
Parkinson’s Disease Therapy – When to Start and What to Choose (2008) (0)
Dopamine dysregulation syndrome in Parkinson's disease - editorial review (2004) (0)
Erasing “the purely arbitrary line”. (2021) (0)
Chapter 17. Early (Uncomplicated) Parkinson's Disease (2008) (0)
An old hypersomnia (2023) (0)
A Landmark Year for Apomorphine – Advancing Parkinson’s Disease Management with New Clinical Evidence (2017) (0)
Mise au point: trauma and Parkinson's disease (1997) (0)
Serendipity and Observations in Functional Neurosurgery: From James Parkinson’s Stroke to Hamani’s & Lozano’s Flashbacks (2022) (0)
Impulse control disorders (2009) (0)
A clinicopathological study of a case of parkin disease (2010) (0)
Biochemical differences exist between clinical phenotypes of progressive supranuclear palsy: Richardson's syndrome and PSP-Parkinsonism (2005) (0)
The Progressive Supranuclear Palsy Association's Fifth International Medical Workshop (2006) (0)
Picturing atrophy patterns of Progressive Supranuclear Palsy (PSP) in vivo using fluid registered MRI (2002) (0)
Why do clinicians request DaT scans? An analysis of requesting practice and outcome in 455 consecutive scans (2010) (0)
Juvenile‐onset parkinsonism (1992) (0)
Stroke/dysphonia/other uses (1993) (0)
ALZHEIMER PATHOLOGY IN PARKINSONS-DISEASE - REPLY (1989) (0)
Unusual tremor associated with a posterolateral thalamic lesion in a drummer (2001) (0)
Fourth Progressive Supranuclear Palsy (PSP-Europe) International Medical Workshop - Abstracts (2004) (0)
Isoniazid plus ethambutol in continuation antituberculous treatment (1980) (0)
Late onset neurological deterioration in phenylketonuria clinical and mri findings (1990) (0)
Speech disorder in ephedrone induced parkinsonism with dystonia (2011) (0)
A multimodal assessment of the brainstem using 3T MRI in PSP and PD (2010) (0)
Analysis of 123I-FPCIT 9DaTSCANTM) binding in normal volunteers and Parkinson's disease (2002) (0)
Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study (2021) (0)
Gowers the researcher (2012) (0)
Chapter 22 – Parkinson's disease (1984) (0)
Investigation of tau gene-specific natural antisense transcript expression and splicing (2008) (0)
Neurophysiological techniques in patients who are secondarily non-responsive to Botulinum toxin (2007) (0)
Olfactory impairment in patients with spinocerebellar ataxias (SCA) (2010) (0)
Severe dysphagia preceding Parkinson's disease (2011) (0)
Chapter 18. Late (Complicated) Parkinson's Disease (2008) (0)
Intranasal a new treatment in Parkinson’s disease. (1990) (0)
Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies (2020) (0)
Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study (2020) (0)
MRI derived brain atrophy rates in PSP and MSA-P: clinical correlations and sample sizes (2006) (0)
Parkinson ’ s disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic de ﬁ cit (SWEDD)? (2016) (0)
Pure akinesia with gait freezing: A 3rd PSP phenotype (2006) (0)
Variation at the LRRK2 locus determines the rate of disease progression in pro- gressive supranuclear palsy (2022) (0)
The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II (2022) (0)
The bicentenary of James Parkinson's “An Essay on the Shaking Palsy” (2017) (0)
101 Motor and non-motor features of prodromal PD (2022) (0)
The Lewy body variant (1990) (0)
Charcot’s Anglophilia (2022) (0)
Joint PSP (Europe) Association/Alzheimer's Society International Medical Workshop - Stowe School, Buckinghamshire, United Kingdom, October 2001 - Abstracts (2002) (0)
G278 Pilot of opportunistic seasonal influenza vaccination for children attending the paediatric emergency department (2017) (0)
A genome-wide association study of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) (2010) (0)
Concerns about the European Academy's Recommendations and Guidelines Regarding Pallidotomy for Parkinson's Disease (2023) (0)
Gerald Malcolm Stern b.1930 d.2018 (2020) (0)
097 Transcranial sonography in the prodromal phase of PD (2022) (0)
Investigation of the role of tau gene transcriptional regulation in neurodegeneration (2011) (0)
DJ-1 (PARK-7) protein in neuronal and glial inclusions in neurodegenerative disorders (2006) (0)
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to race: Post-hoc analysis from double-blind combined BIPARK-I and II data (2019) (0)
In memoriam (1999) (0)
degeneration progressive supranuclear palsy and corticobasal gene in tau haplotype association analysis of the Linkage disequilibrium fine mapping and (2005) (0)
Reflexive and volitional saccadic eye movements and their changes in age and progressive supranuclear palsy (2022) (0)
JNNP245746 1107..1111 (0)
The prevalence of impulsive compulsive behaviors in patients treated with apomorphine infusion: a retrospective analysis (2021) (0)
Acknowledgment of Reviewers (2003) (0)
P3-168 DE NOVO deletions of the MAPT locus associated with learning disability: Further evidence of genetic instability at 17q21.31 (2006) (0)
Reply to Comment on “Patients’ Postjudice of Tele‐Neurology for Movement Disorders” (2022) (0)
Erratum: [ 12 I]-FP-CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor (Annals of Neurology (2003) 53 (489-496)) (2003) (0)
Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach (2023) (0)
Opicapone analysis of health economic costs in clinical practice in Parkinson's disease UK patients with motor fluctuations: Findings from the OPTIPARK study (2021) (0)
OFF/-ON-time changes after switching from entacapone or placebo to opicapone in patients ending the BIPARK-I extension study on opicapone 50-mg (2020) (0)
P1-386 Analysis of the involvement of DJ-1 (Park-7) in AD, Pick’s and PSP (2006) (0)
096 Motor and non-motor features of prodromal Parkinson’s in idiopathic anosmia (2022) (0)
Apomorphine therapy in Parkinson's disease: Clinical neuropharmacology and practical use (2000) (0)
A sandwich ELISA for measuring tau isoforms in neurodegenerative tauopathies (2008) (0)
Polymorphism strongly associated with PSP alters MAPT transcription (2011) (0)
Atypical parkinsonism in the French West Indies - reply (1999) (0)
Editorial (1999) (0)
Demonstration of the neuroanatomy of the midbrain using high field MRI (2007) (0)
thrombosis . cord infarction and basilar artery Giant cell arteritis with spinal (0)
Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation (2015) (0)
1.133 INVESTIGATING THE ROLE OF OLIGODENDROCYTE PRECURSOR CELLS IN MULTIPLE SYSTEM ATROPHY AND RELATED DISORDERS (2012) (0)
HOW SHOULD PATIENTS WHO DEVELOP PARKINSONS-DISEASE BE MANAGED IF THEY NEED TO CONTINUE TO TAKE MONOAMINE OXIDASE-A INHIBITORS (1992) (0)
Redundant Publication (1997) (0)
Familial Parkinsonism and early onset Parkinson's disease: Phenotypic and genotypic characterization in a Brazilian Movement Disorders clinic (2007) (0)
To Investigate Olfactory Impairment in Cerebellar Ataxia (2012) (0)
118 The new Bradykinesia Akinesia Incoordination (BRAIN) test: an online test of upper limb movement (2012) (0)
Bing-Neel syndrome presenting with Parkinsonian features: A case report (2016) (0)
Issue Information (2023) (0)
0854 Camptocormia: what is the cause? (2012) (0)
PATH54 Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study (2010) (0)
Organisational and neuromodulatory underpinnings of structural-functional connectivity decoupling in patients with Parkinson’s disease (2021) (0)
Digital biomarkers in Parkinson's disease: missing the forest for the trees? (2023) (0)
Selegiline and mortality in Parkinson's disease: anotherview [letter; comment] (1997) (0)
Piribedil efficacy in monotherapy (150 to 300 mg/day) in de novo parkinsonian patients: A 6-month planned intermediate of the 2-year Parkinson-regain study (2004) (0)
Charcot: Buddhist Leanings? (2021) (0)
Letter: Bromocriptine in parkinsonism. (1975) (0)
Erich Harnack and apomorphine: An historical insight (2012) (0)
Reduced striatal [(123)I]FP-CIT SPECT in acquired hepatocerebral degeneration (2013) (0)
Optimising classification of Parkinson’s disease based on motor, olfactory, neuropsychiatric and sleep features (2021) (0)
Evidence-Based Reviews and Guidelines: Let's Avoid Future Confusion. (2022) (0)
Face-making: task-specific facial tensions and grimacing in musicians (2019) (0)
The new bradykinesia akinesia incoordination (BRAIN) test: People with Parkinson's disease versus healthy controls (2012) (0)
P2.026 Optimizing olfactory testing for the diagnosis of Parkinson's disease (2009) (0)
A UK comparison of Sniffin' Sticks (SS) and University of Pennsylvania (UPSIT) Smell Identification Tests in Parkinson's disease (2006) (0)
SPG11 sequencing in worldwide populations of familial and sporadic spastic paraplegia patients reveals frequent mutations and the common association of parkinsonian features (2013) (0)
Parametric mapping of I-123-FPCIT (DaTSCAN) binding in normal volunteers and Parkinson's disease (2001) (0)
Levodopa induced chorea in Meige syndrome. (1983) (0)
Further analysis of the association of tau with progressive supranuclear palsy. (1999) (0)
A Patient With Rapidly Progressive Dementia and Supranuclear Gaze Palsy: A Memorable Lesson on Prion Disorders (2012) (0)
Parkinson ' s syndrome . neurodegenerative disorders presenting with Absence of disease related prion protein in (0)
Picture Quiz Progressive dysphagia, dysarthria, dystonia, and tremor (2010) (0)
Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials. (2023) (0)
Ray of Hope (1993) (0)
New version of the UPDRS (MDS-UPDRS): Factor analysis (2008) (0)
Drug-cue elicited frontal and limbic dysfunction in Parkinson's disease patients with dopamine dysregulation syndrome (2012) (0)
1-methyl-4-phenyl-1,2,3,6-tetradropyridine-induced parkinsonism in the commonmarmoset (1984) (0)
Potential clinical applications of FP-CIT: Experience from studies of 140 subjects (1999) (0)
Predicting non-motor features of Parkinson's disease (2010) (0)
Single Exon Rearrangements of GTP Cyclohydrolase I in Two Families with Dopa-Responsive Dystonia (2009) (0)
To Investigate Olfactory Impairment in Cerebellar Ataxia (P05.015) (2012) (0)
A film of patients with movement disorders made in queen square in the mid-1920s by Samuel Kinnier Wilson (2008) (0)
Listening with intent (2019) (0)
Theuse ofbotulinum toxin inthetreatmentof adductor spasmodic dysphonia (1993) (0)
Perceptual decision making and Parkinson's disease. A direct comparison of deep brain stimulation, addictive behaviours and dopamine agonist therapy (2014) (0)
Chapter 6 Progressive Supranuclear Palsy and Corticobasal Degeneration (2007) (0)
Mucuna pruriens and extracts from it for the treatment of neurological diseases (2003) (0)
Investigating the role of oligodendroglial precursor cells in multiple system atrophy and progressive supranuclear palsy (2011) (0)
Georges Simenon, Inspector Maigret and his relevance to the practice of Neurology. (2017) (0)
POC08 A case of central and peripheral vestibular vestibular failure (2010) (0)
Influence of demographic characteristics on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study (2021) (0)
Immunohistochemical Detection of Fosb/Delta fosb-Like Proteins Maps Areas of Maladaptive Neuroplasticity in the Post-Mortem Parkinsonian Brain (2010) (0)
Comprar Imaging of Movement Disorders, An Issue of Neuroimaging Clinics | Tarek Yousry | 9781437712421 | Saunders (2010) (0)
Subject Index Vol. 27, Suppl 1, 1987 (1987) (0)
Manganic Parkinsonism in Chile and the introduction of levodopa (2015) (0)
Nineteenth century neurology: newly discovered photographs from the National Hospital, Queen Square (2009) (0)
49. 99Tcm-HMPAO rCBF SPECT in corticobasal degeneration (1992) (0)
Characteristics, treatment patterns and disease burden of people with Parkinson's disease in the Parkinson's disease real-world impact assessment (PRISM) study (2020) (0)
IN60-TH-03 Parkinsonian sphinx (2009) (0)
Letters to the Editor (0)
Tau gene polymorphism influences risk of sporadic tauopathy by allele-specific changes in transcription and alternative splicing (2010) (0)
From Sgt. Pepper to Dreamachines: My Scientific Odyssey With William S. Burroughs. (2017) (0)
Determining the anatomy of the subthalamic nucleus and substantia nigra on MRI using 9.4Tesla (2008) (0)
Spinal changes underlying postural deformity in Parkinson's disease (2011) (0)
The role of 4E-BP1, a putative LRRK2 interactor in the pathology of IPD and in G2019S LRRK2 mutation cases (2011) (0)
Neural correlates of hypersexuality in Parkinson's disease (2012) (0)
Gowers' Queen Square Case Notes on Chorea (S59.004) (2012) (0)
Unimpaired reward learning but elevated temporal discounting in Parkinson's disease patients with impulse control disorders (2009) (0)
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of monoamine-oxidase-b inhibitors and dopamine agonists: The real-world OPTIPARK study (2021) (0)
THAP1 mutations and dystonia phenotypes: A metanalysis, genotype phenotype correlations and identification of novel mutations (2012) (0)
Progressive dysphagia, dysarthria, dystonia, and tremor (2010) (0)
Impulsive Sensation Seeking mediates cigarette, alcohol and caffeine intake in Parkinson's disease (2005) (0)
Gowers the writer and lecturer (2012) (0)
SK-AND-F 101468, A NOVEL DOPAMINE D2 AGONIST IN PARKINSONS-DISEASE (1990) (0)
Clinicopathological correlation of progressive supranuclear palsy presenting with corticobasal syndrome (2012) (0)
Dementia in parkinsonism - Preface (1997) (0)
Editorial (2000) (0)
CAN THERAPY MODIFY NATURAL EVOLUTION OF PARKINSON'S DISEASE? - CONTRA (2011) (0)
Concerns About the European Academy's Recommendations and Guidelines Regarding Pallidotomy for Parkinson's Disease (2023) (0)
Neuropsychiatric Features of Punding and Hobbyism in Parkinson's Disease (2021) (0)
Dystonic features in adult sporadic tremor dominant Parkinson's disease: A case series (2009) (0)
Handwriting in Parkinson's disease: Systematic review and preliminary study (2016) (0)
Cross-sectional clinical description of a large prospective cohort of patients with progressive supranuclear palsy or multiple system atrophy: The NNIPPS project (2003) (0)
Apprentice years 1861–2 (2012) (0)

This paper list is powered by the following services:

Other Resources About Andrew Lees

What Schools Are Affiliated With Andrew Lees ?

Andrew Lees is affiliated with the following schools:

Andrew Lees 's Academic­Influence.com Rankings

Andrew Lees 's Degrees

Why Is Andrew Lees Influential?

Andrew Lees 's Published Works

Published Works

Other Resources About Andrew Lees

What Schools Are Affiliated With Andrew Lees ?

Image Attributions

Andrew Lees 's AcademicInfluence.com Rankings